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 1. INTRODUCTION 
 
1.1 A perspective on malaria 
Malaria is an infectious disease caused by protozoon parasites of the genus Plasmodium 
and transmitted by the bite of an infectious female Anopheles mosquito. It is most 
common in tropical climates, but also occurs in many sub-tropical regions. Malaria 
infects vertebrates including humans, monkeys, birds, reptiles, and rodents. There are 
four Plasmodium species causing a clinically relevant infection in humans: Plasmodium 
falciparum, Plasmodium vivax, Plasmodium malariae and Plasmodium ovale. Recently, it has 
been reported that Plasmodium knowlesi, a monkey malaria parasite in certain forest areas 
of South-East Asia, infects humans more frequently than previously known (Singh et al., 
2004).  
P. vivax is causing tertian malaria with almost 40% of the world’s population at risk. 
Although often regarded as causing benign and self-limiting infection, there is 
increasing evidence that overall burden, economic impact and severity of P. vivax 
infection are underestimated (Mendis et al., 2001; Price et al., 2007). According to WHO, 
there are 132-391 million clinical cases per year. In recent years, increasing numbers of 
cerebral malaria and fatalities due to P. vivax mono-infection have been reported (Tjitra 
et al., 2008; Tanwar, et al., 2011). P. ovale is a more infrequent cause of tertian malaria and 
often presents with low grade parasitaemia. P. malariae infection is also a mild variant of 
malaria but it can cause renal complications especially in children (Garcia, 2010). P. 
falciparum causing malaria tropica, later abbreviated as “falciparum malaria”, causes the 
most severe clinical symptoms and is potentially lethal in human due to a high 
reproduction rate and the capability to invade erythrocytes of all ages, thus resulting in 
very high parasitaemia. Furthermore, infected erythrocytes acquire the ability to adhere 
to the endothelium of blood vessels causing obstruction of microcirculation, leading to 
poor perfusion of host tissues, anaerobic metabolism and hypoxia resulting further in 
multiple organ failure (Miller et al., 2002; Chenb et al., 2000).  
Malaria cases present with a large range of disease manifestations ranging from 
asymptomatic infection to severe malaria and death. Some factors are involved in the 
clinical outcome, including host immunity, parasite virulence and geographical and 
social factors. Host factors determining the clinical manifestation are age, immune status, 
proinflammatory cytokines, nutrition and genetic background such as sickle cell trait, 
thalassaemia and ovalocytosis. The known parasite factors involved are drug resistance, 
multiplication rate, invasion pathways, cytoadherence, antigenic variation and malaria 
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toxin. Geographical and social factors such as transmission intensity and population of 
circulating parasite, access to treatment, cultural and economic factors and political 
stability also affect the disease outcome (Greenwood et al., 1991; Miller et al., 2002). 
Malaria symptoms appear seven days or more after the infective mosquito bite (minimal 
incubation period). The primary symptom all types of malaria is the ‘malaria ague’ 
(chills and fever). Symptoms for uncomplicated malaria are non-specific acute febrile 
illness, difficult to differentiate from other febrile diseases. Falciparum malaria in non-
immune patients, if not treated timely, can progress rapidly to severe illness often 
leading to death. In highly endemic areas, mostly infants and young children are 
affected by severe and fatal malaria since semi-immunity develops and protects most of 
the elder children and adults from severe disease. It is estimated that 0.1-0.5% of all 
falciparum malaria infections result in severe life-threatening disease (Greenwood et al., 
1991). This is only a small proportion, but the overall number of malaria infections is 
huge enough to result in many cases with life-threatening infection (Snow et al., 2005). 
In severe malaria one or more of the following symptoms frequently develop: severe 
anaemia, prostration, convulsion and respiratory distress, metabolic acidosis or cerebral 
malaria with impaired consciousness and coma (Mackintosh et al., 2004; WHO, 2000). 
Early diagnosis and treatment can reduce disease severity, prevent deaths and 
contribute to the reduction of malaria transmission. Widespread implementation of 
malaria case-management using effective anti-malarial drugs such as artemisinin-based 
combination therapy (ACT) and preventive tools such as insectiside-treated bednets, 
reduced all childhood deaths in Africa by near 20% (Lengeler, 2004). However, 
resistance to malaria treatment has spread very rapidly, subverting malaria control 
efforts. Intensive research efforts to develop an efficacious malaria vaccine have been 
made over the past 20 years but remained elusive because of the complexity of the 
parasite. 
 
1.2 Plasmodium knowlesi 
Plasmodium knowlesi is defined as a zoonotic malaria parasite and transmitted by 
mosquitoes of the Anopheles leucosphyrus group. At present, the natural hosts of P. 
knowlesi have been identified as long-tailed macaques (Macaca fascicularis), pig-tailed 
macaques (Macaca nemestrina) and leaf monkeys (Presbytis melalophos) (Eyles et al., 1962). 
In 2004, a large number of P. knowlesi infections in humans was reported from Malaysia 
(Singh et al., 2004). Other observations and studies followed recently, including reports 
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about human fatalities with P. knowlesi (Cox-Singha et al., 2008) and cases from Thailand 
(Jongwutiwes et al., 2004), China (Zhu et al., 2006), Singapore (Ng et al., 2008), the 
Philippines (Luchavez et al., 2008) and imported by tourists (USA, Finland, Sweden) 
who had traveled to South-East Asian countries. These findings raised a legitimacy to 
claim P. knowlesi as the fifth causative agent of malaria in humans. 
Humans are susceptible to infections and can be infected anywhere within the range of 
distribution of the specific vector if infected monkeys are present (Collins and Barnwell, 
2009).  The range of the A. leucosphyrus group overlaps with the long-tailed and pig-
tailed macaques. The known distributions of A. leucosphyrus group are: Southern 
Thailand, Malaysia, Indonesia, Philippines (Manguin et al., 2008). They are also found in 
Bangladesh, China, India, Myanmar, and Sri Lanka (Sallum et al., 2005). Long-tailed 
macaques are widespread throughout the islands of Southeast Asia and mainland Asia 
(Fittinghoff and Lindburg, 1980; Groves, 2001). Pig-tailed macaques have a wide range 
throughout Southeast Asia as well (Groves, 2001; Choudhury, 2003). Therefore, naturally 
acquired human P. knowlesi infections have been acquired within this range (Figure 1.1) 
(Cox-Singhb and Singh, 2008). Regarding the large distribution of the vector (A. 
leucosphyrus group) and the natural host of P. knowlesi  (Macaca species) in Southeast 
Asia, it was very likely to find P. knowlesi in Indonesia. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Zone where P. knowlesi malaria and the anopheline vectors may likely 
cause infection in humans. P. knowlesi is potentially distributed as far north as Taiwan, 
east as Sulawesi, south to Java in Indonesian archipelago and as far west as Myanmar 
and the eastern edge of India (Baird, 2009). 
 
The prevalence of naturally acquired knowlesi malaria in humans may be 
underestimated (Jongwutiwes et al., 2004). Misdiagnosis often occurs by microscopy 
because the early blood stages of P. knowlesi morphologically resemble P. falciparum, the 
mature trophozoites and schizonts may present characteristics of P. malariae. Therefore, a 
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patient infected by P. knowlesi is most likely, but not exclusively, to be diagnosed as 
infected by P. malariae (White, 2008). 
Several studies in describing the clinical feature of human P. knowlesi infection by human 
volunteers challenged with P. knowlesi showed the infection as mild to severe malaria 
with most attacks terminating spontaneously after two weeks (Coatney et al., 1971). 
Another study reported initial fever up to 39oC but later fever raised up to 41oC, which 
appeared daily (quotidian fever) until 10 days and finally diminished spontaneously. 
Most cases had less than 1% parasitaemia, but one patient showed 12% parasitaemia 
(Milam and Kusch, 1938). Of interest, African people seemed to be difficult to infect with 
P. knowlesi, four of six challenged developed only very mild disease and the other two 
none at all. P. knowlesi shares very similar Duffy-like receptors on erythrocytes as occurs 
in P. vivax, thus the Duffy receptor negative phenotype probably protects humans 
against infection by P. knowlesi (Chin et al., 1968; Baird, 2009). 
 
1.3 The global distribution of Plasmodium falciparum malaria  
Malaria is found in 108 countries of the world (WHO, 2010) and every year 500 million 
cases of malaria and an estimated 1-3 million deaths is reported. In 2007, 2.37 billion 
people lived in areas at any risk of P. falciparum transmission worldwide, 26% located in 
Africa, 62% in South east Asian and Western Pacific region and the rest is located in 
American, eastern Mediterranean and European regions (Guerra et al., 2008). Most 
malaria cases and deaths occur in sub-Saharan Africa (Figure 1.2). 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. The spatial distribution of P. falciparum malaria PfPR2-10 prediction 
stratified by endemicity class. They are categorized as low risk (PfPR2-10 <5%), 
intermediate risk (5%<PfPR2-10<40%) and high risk (PfPR2-10 >40%) areas. The rest area is 
classified as unstable risk (medium grey area if PfAPI<0.1 per 1,000 pa) or no risk (light 
grey, if PfAPI=0 per 1,000 pa) (Hay et al., 2009). 
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In Indonesia, 132.8 million of 230 million people live in malaria endemic areas in 2010. 
Of these, 70.3% lived in areas of unstable transmission. Among those living in stable 
transmission, 93.39% were at low risk, 6.6% at intermediate risk and only 0.01% at high 
risk of transmission (Elyazar et al., 2011). In 2009, 544 thousands confirmed malaria cases 
with 900 deaths were reported according to WHO (SEARO-WHO, 2010). 
The intensity of malaria transmission depends on factors related to the parasite, the 
vector, the human host, and the environment. There are approximately 33 different 
Anopheles vector species around the world. Some species are more significant than others 
as vectors because of variations in susceptibility to the parasite or the propensity to bite 
humans (Kiszewski et al., 2004). Human immunity is another important factor, 
especially among adults in areas of moderate or intense transmission conditions. 
Immunity is developed over years of exposure. Though it rarely results in sufficient 
protection, meaning asymptomatic parasitaemia, like in high transmission areas, 
frequent exposure does decrease the risk of severe malaria infection. For the children 
until the age of 6 months, they develop only mild symptoms and low parasitaemia 
(Snow et al., 1997) as the result of passive transfer of maternal antibodies and persistence 
of haemoglobin F (Sehgal et al., 1989; Hogh et al., 1995). From around 6 months, children 
become susceptible to severe disease and death. For this reason, most malaria deaths in 
Africa occur in young children, whereas in areas with lower transmission and less 
immunity, all age groups are at risk.  
Transmission also depends on climatic and ecological factors. These factors are required 
for the abundance and survival of the anopheline mosquitoes and for the development 
of sporozoites within the vector. Beside the climatic conditions, transmission can be 
influenced by human activities such as urbanization, mass population movement, 
agricultures and malaria control program.  
1.4 Plasmodium falciparum life cycle 
The life cycle of P. falciparum includes sexual and asexual reproduction, involving both 
human and Anopheles spp mosquito hosts. During the entire cycle, there are several 
changes (Figure 1.3). When an infected female Anopheles mosquito injects saliva during 
blood meal to prevent coagulation, it inoculates 1-100 infective sporozoites into the 
blood stream, infecting the human (Rosenberg et al., 1990; Ponnudurai et al., 1991). The 
blood and probably the lymphatic system transport the sporozoites into the liver where 
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5-10% successfully invade hepatocytes (Ferreira et al., 1986). They differentiate into 
hepatic schizont in which around 30,000 daughter merozoites develop (Amino, 2006). 
After 5-14 days the schizont ruptures and spreads thousands of merozoites into the 
blood stream, they invade erythrocytes. The development from sporozoite injection to 
hepatocyte rupture is called the exo-erythrocytic cycle. During this stage, the host stays 
asymptomatic.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Schematic representation of P. falciparum life cycle. The different phase of 
P. falciparum life cycle, (A) the exo-erythrocytic cycle occurs in the hepatocytes from 
sporozoite injection to hepatocyte rupture; (B) asexual reproduction in erythrocytes and 
differentiation into gametocytes in the erythrocyte cycle; (C) the sexual reproduction in 
the mosquito’s mid gut and the completion of the life cycle by injection of sporozoites 
into the new host (CDC, www.dpd.cdc.gov/dpdx). 
 
The asexual reproduction begins in the erythrocytes. After invasion, the merozoite 
grows and develops into a small ringform. The cells are in the G-phase and increase in 
size, called trophozoite stage. The transition into the S-phase with DNA duplication and 
membrane separation leads to the schizont form, containing around 16-32 merozoites. 
The infected erythrocyte (IE) ruptures and releases these daughter merozoites into the 
blood stream where they each invade a fresh erythrocyte and start the new cycle. The 
entire cycle from invasion to rupture of the erythrocyte takes around 48 hours. Once 
these parasites begin affecting erythrocytes, the disease becomes clinically apparent. It is 
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thought that the intermittent release of merozoites causes the symptoms of malaria in the 
host by stimulation of endogenous release of pyrogens. The majority of merozoites will 
again infect erythrocytes and develop into schizonts. A small number will differentiate 
into male and female gametocytes within erythrocytes. These sexual forms are 
responsible for transmission of P. falciparum through ingestion by feeding mosquitoes. 
When a female anopheline mosquito feeds on the blood of an infected person, it ingests 
gametocytes. Inside the mosquito’s midgut, the female gametocytes develop into 
macrogametes and the male gametocytes exflagellate and form microgametes which 
fertilize the macrogametes by fusion, forming motile zygotes called ookinetes. The 
diploid ookinetes cross the midgut membrane, undergo meiosis and adhere onto the 
exterior site of the gut wall. Here, they undergo several rounds of mitosis to form oocyst 
(sporogony). This step is called sporogonic cycle. Each oocyst releases thousands of 
motile haploid sporozoites into the mosquito’s body cavity, from where they migrate 
into the mosquito’s salivary glands. During the next blood meal, they are injected 
together with the saliva into a new host and the cycle is completed. 
 
1.5 Plasmodium falciparum erythrocyte membrane protein–1 (PfEMP-1) 
During the erythrocytic cycle, P. falciparum expresses a large and highly polymorphic P. 
falciparum erythrocyte membrane protein-1 (PfEMP-1), which is exported from the 
parasite to the surface of infected erythrocyte approximately 18 hours post invasion 
onwards. This protein has been linked to two key phenomena responsible for the 
pathology associated with P. falciparum infection: cytoadherence of IE and 
immunoregulatory effects on host immune cells through binding to other host receptor 
and antigenic variation with consequent immune evasion. 
PfEMP-1 is ~250 – 350 kDa in size and varies in domain composition and binding 
specificity. The architecture of PfEMP-1 is complex. The extracellular part protrudes 
from the erythrocyte membrane into the host’s blood plasma being the most variable 
part of the protein. It contains an N-terminal segment (NTS) followed by a segment 
composed of three binding domain types: Duffy binding-like (DBL) domain, cysteine-
rich interdomain regions (CIDR) and C2 domain. The NTS is semi-conserved and located 
at the N-terminal end of PfEMP-1. It contains sequence features sufficient for transport 
beyond the parasitophorous vacuole that surrounds the intraerythrocytic parasite (Hiller 
et al., 2004; Marti et al., 2004). The DBL domain is an adhesive region that binds a variety 
of different receptors. Based on conserved sequence stretches and conserved cysteine in 
the sequences, the DBL domain is classified into six different types: α, β, γ, δ, ε and χ. 
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Further sequence analysis revealed that each DBL domain is divided into 10 semi-
conserved blocks (A-J) and 10 variable blocks (1-10). The semi-conserved blocks contain 
a higher number of invariant or bio-chemically-conserved residues that are presumably 
important for domain folding. The absolute number of cysteine residues differs 
significantly between DBL domains of PfEMP-1. The CIDR domain consists of semi-
conserved stretch and is classified into three different types: α, β and γ. The last domain 
type C2 involved in calcium-dependent phospholipid binding and membrane targeting 
process such as sub-cellular localization (Smithb et al., 2000). The intracellular part or the 
acidic terminal sequence (ATS) is rather conserved and may function as an anchor by 
interaction with erythrocyte skeleton proteins (Oh et al., 2000) and additional parasite 
proteins such as KAHRP (Rug M et al., 2006; Waller et al., 2002). 
The PfEMP-1 proteins have related protein architecture, but the sequence, number, 
location and type of domains differ significantly, usually they contain between two and 
seven DBL domains and one and two CIDR domains (Figure 1.4). Thirty-one different 
architectural types are described from the three sequenced parasite var repertoires 
(Kraemer et al., 2007). Because the domain architecture is variable, PfEMP-1 domains are 
identified by position in the protein and by type, for example DBL1α represents the first 
domain after the NTS. Semi-conserved head structures like DBL1α–CIDR1α, DBL2β-C2 
and DBLδ–CIDRβ make up a protein prototype and are found in nearly all PfEMP-1 
molecules. By integration of additional domains, the flexibility of protein may increase 
and provides an extra advantage, such as the ability to bind multiple receptors (Smithb et 
al., 2000). 
 
 
 
 
 
 
 
 
Figure 1.4. Schematic architecture of PfEMP-1. (a) A small PfEMP-1 protein consists of 
minimal arrangement i.e. the NTS domain followed by the semi-conserved DBL1α-
CIDR1α and the ATS domain. (b) A larger variant of PfEMP-1 including the semi-
conserved head structure DBL1α-CIDR1α, tandem association DBL2β-C2 and DBL5δ-
CIDR2β and additional DBL and CIDR domain. The host cell receptors involved in 
binding are indicated at the respective PfEMP-1 binding-domain (Smith et al., 2001). 
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1.6 var gene family 
PfEMP-1 is encoded by the highly divers var gene family consisting of approximately 60 
genes per haploid genome. The var genes have two exons with a ~170 bp to 1.2 kb intron. 
The first exon is highly polymorphic, encodes the extracellular part of protein and trans-
membrane (TM) domain and varies in size between 3.5 and 9.0 kb. The second exon, in 
contrast, is relatively short, more conserved and encodes the intracellular acidic terminal 
segment and the size is between 1.0 and 1.3 kb (Figure 1.5b) (Gardner et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Genomic organization and the features of var genes. (a) All 14 P. falciparum 
chromosomes have a common overall organization in sub-telomeric regions, with non-
coding repeats of variable size called TARE (telomere-associated repeat elements), 1-6 
located next to telomere repeats. The region is followed by a member of var gene family 
with the second var gene transcribed in the opposite direction. rif gene are often located 
between var genes. Several tandem arrayed var gene clusters are also found in the 
centromere. var genes classification based on the upstream promoter type (Ups) and 
chromosomal location, arrows indicate the direction of transcription. UpsB, UpsA and 
UpsE located at sub-telomere but have opposite transcriptional direction; Ups C located 
at central chromosomal region with the transcriptional direction toward centromere. (b) 
A common feature of the var gene family. All members contain two exons separated by 
conserved intron. Exon 1 encodes for the highlypolymorphic extracellular domain and 
Exon 2 is more conserved and encodes the intracellular region (Scherf et al., 2008). 
 
In 3D7, var genes present on all 14 chromosomes and approximately 60% of var members 
are located at sub-telomeric regions, with the remainder in chromosome central regions 
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(Gardner et al., 2002). One to three var genes exist at telomeres pointing in different 
direction, either in tail-to-tail (most frequent), head-to-tail, or head-to-head orientation 
relative to each other with one or more rif gene in between. The central var genes appear 
single or in groups that are nearly always tandem arrayed in the head-to-tail orientation, 
containing three to seven var genes (Figure 1.5a) (Kyes et al., 2007). 
The chromosomal location and orientation of var genes are associated with particular 
types of 5’-flanking regions called Ups. Based on the 5’-Ups type, domain structure of 
the encoded protein and sequence similarities in coding and non-coding regions, var 
genes can be classified into three major group: A, B and C (Gardner et al., 2002; Lavstsen 
et al., 2003). UpsA type is located sub-telomeric and transcribed towards the telomere. 
UpsB type is telomeric and transcribed towards the centromere, while UpsC type is 
located in the center of chromosome (Figure 1.5a). There is also a subset of var genes, the 
B/C group, which has UpsB-like promoters but present in central chromosomal regions 
and B/A group which present in sub-telomeric chromosomal region but have gene 
orientation to centromere (Lavstsen et al., 2003). This general gene organisation is 
retained across the parasite isolate; it has been postulated to influence the functional and 
antigenic specialization of PfEMP-1 proteins through gene recombination hierarchies 
(Kraemer and Smith, 2003). 
Apart from var groups A, B, and C, there are three unusual semi-conserved var genes; 
var1CSA, var2CSA and type 3 var gene. According to their chromosomal location and 
transcriptional direction, var1CSA and var2CSA belong to var group A, however both 
have a distinct 5’-Ups, var1CSA has an UpsD, which is now grouped with UpsA 
(Kraemer et al., 2007) and var2CSA has an UpsE. And type 3 var has UpsA. All three 
genes are exceptionally conserved across parasite isolates and constitute possible gene 
orthologs but they share little sequence identity with other members of the var gene 
family, posing the hypothesis that these genes primarily undergo self-self recombination 
(Kraemer and Smith, 2006).  
 
1.7 var gene diversity 
Since the var gene repertoire is around 60 copies per haploid genome, it is not surprising 
that large sequence diversity exists between different isolates (Su et al., 1995). A study 
using in situ-hybridization techniques found that genetically diverse parasites contained 
essentially, although not completely, non-overlapping var gene repertoires, indicating 
the extreme diversity of var genes (Freitas-Junior et al., 2000). Global sequence 
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comparisons have also demonstrated the immensity of var gene diversity with nearly no 
overlaps among repertoires from different geographical origins (Barry et al., 2007) nor 
between isolates (Kaestli et al., 2004; Bull et al., 2005). However, the mechanisms driving 
var gene diversity remain only partially understood. Genetic diversity can be generated 
by recombination and rearrangement during the sexual (meiotic) (Taylorb et al., 2000) or 
asexual (mitotic) phase of the parasites life cycle (Duffy et al., 2009). A study analyzing 
progeny clones from two genetic crosses supported the high rate of recombination in var 
genes leading to a new var forms via gene conversion involving the nuclear structure as 
the hot spots of recombination (Scherf et al., 2008). Another approach reported that sub-
telomeric var genes are in part responsible for var gene diversity by mechanism of 
intragenic recombination and re-arrangement between two var genes (Taylorb et al., 
2000). Recombination preferentially occurs within genes which have a common genome 
location and gene orientation, and is likely influenced by 5’-flanking regions and gene 
coding similarity (Kyes et al., 2007). This recombination hierarchy may be shaping the 
var gene repertoire and influencing the evolution of the gene family. 
 
1.8 Regulation of var gene expression 
Several important findings regarding var gene expression have been reported. First, 
expression of var genes is stage specific and temporally regulated during parasite 
development (Kyes et al., 2000). Second, telomeric as well as centromeric var genes 
located on different chromosomes can be selected for expression. Third, the expression 
of var genes is mutually exclusive, i.e. only one member of the var gene family is 
expressed on the surface of an infected erythrocyte (Chen et al., 1998; Scherf et al., 1998). 
The expression of PfEMP-1 is developmentally regulated as the protein appears on the 
surface of the infected erythrocyte around 16-18 hours post invasion (Gardner et al., 
1996). The control of var gene transcription is stage-specific and tightly regulated. Two 
opposing results from two different approaches were reported. Northern blot analysis 
showed that the major var mRNA transcript encoding the PfEMP-1 was present at 
maximum amount in late-ring stage (3-18 h post-erythrocyte invasion) declining until 
barely detectable over the following 6 h by trophozoite stage, suggesting that the control 
of var gene expression is maintained at the level of transcriptional initiation (Kyes et al., 
2000). In contrast were results from reverse transcription-PCR (RT-PCR) experiments 
detecting mRNA transcripts within a single IE. Multiple var transcripts were present in 
ring stages with one dominant transcript present in the trophozoite stage which implies 
a post-transcriptional mechanism of control (Chen et al., 1998; Scherf et al., 1998). Of 
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interest, a repression of var gene transcription during intra-erythrocytic development of 
the parasite occurs at different times depending on the chromosomal location of the var 
gene. Sub-telomeric var genes are only expressed up to 18 hours post infection and 
inhibition of sub-telomeric var gene transcription occurs between 4 and 8 hours before 
transcription of centrally located var genes. This indicates that the structural differences 
of the promoter types reflect functional and regulatory differences in transcriptional 
repression (Voss et al., 2003). 
var gene expression follows the rule of mutually exclusive expression, with only one 
gene being expressed by an individual parasite at a given time (Scherf et al., 1998). The 
mutually exclusive expression is not based on a negative feedback from the var protein 
product itself but regulated at the level of transcription initiation level (Kyes et al., 2007) 
and involves multiple layers of control including the epigenetic factors.  
The first layer is the structure of the two transcriptionally active promoters of var genes; 
one upstream of the first exon (5’ var promoter) encoding mRNA and the second within 
an intron (var intron promoter) that leads to expression of sterile (non-coding) RNA and 
has regulatory functions both as a silencer and in the recognition of var genes (Deitsch et 
al., 2001; Frank et al., 2006; Dzikowski et al., 2007). The interaction between these two 
promoters and the presence of sterile RNA (Calderwood et al., 2003; Kyes et al., 2003) 
seems to play an important role in the silencing process of var genes.  
The second layer is the epigenetic memory of var genes, i.e. once the transcriptional 
status of an individual var gene has been established, the state (either active or silent) 
tends to be maintained through multiple cell cycles with only rare switching (Horrocks 
et al., 2004; Frank et al., 2007). Thus, the transcriptional state of each gene is 
‘remembered’ from one cell cycle to the next and this memory is encoded into the 
genome through a series of ‘marks’ placed at each gene. In addition, the particular 
modification of histone including acetylation and methylation plays a significant role in 
‘bookmarking’ either active or silent genes (Duraising et al., 2005, Freitas-Junior et al., 
2005; Comeaux and Duraising, 2007).  
The third layer is the sub-nuclear organization, where the silent genes tend to localize 
within regions of the nucleus that contain primarily condensed heterochromatin and 
active transcription commonly takes place in euchromatic regions in which chromatin is 
loose and open for transcription. Study using var-specific probes showed that all var 
genes localize mostly at the nuclear periphery regardless of chromosomal location or 
their activation state and var genes appear to move upon changes in their transcriptional 
Introduction 
______________________________________________________________________________ 
 13
activity. A model was proposed that the telomeric clusters are located within 
heterochromatin region of the nuclear periphery whereas upon activation it moves to 
another location of the nuclear periphery where the chromatin is open for transcription 
(Ralph et al., 2005). 
 
1.9 Antigenic variation and var gene switching 
P. falciparum is able to avoid clearance by the human immune system which depends on 
its capacity to continuously alter the surface exposed antigenic proteins which are 
vulnerable to antibody recognition and attack, this process is called antigenic variation 
(Dzikowski and Deitsch, 2009). The antigenic variation mechanism is carried out by 
successive switching of expression of var gene family members (Horrocks et al., 2004). 
This allows parasites to modify the antigenic and functional properties of IE resulting in 
modified adhesive phenotypes and possibly altered virulence. Moreover, antigenic 
variation allows parasites to establish persistent chronic infections. 
In vitro observation has shown that the rate of switching is an intrinsic property of each 
var gene, different var genes switch on and off at different rates, and no preferential 
switching between central or telomeric var gene occurs (Horrocks et al., 2004). However, 
another study suggested that switching relies on an epigenetic process and correlates  
with chromosomal location, and that in clonal parasite populations, central var genes 
have extremely stable expression pattern and rarely undergo transcriptional switches in 
the absence of selection. Sub-telomeric var genes on the other hand readily switched to 
alternative var loci (Frank et al., 2007).  
Parasites cultured in vitro switched spontaneously at a rate of 2% in the absence of 
immune pressure (Roberts et al., 1992). If the in vivo switching rate would occur to the 
same degree, the parasite would exhaust its variant repertoire, instead of new 
repertoires of variant antigens becoming available for selection through recombination 
events. Nevertheless, by combining new data derived from naive human hosts with a 
simulation model, data suggest that during the acute stage of infection, switching rates 
per generation is ∼18%, this is even much faster than initially thought (Gatton et al., 
2003), so it is likely that switching rate has a wide range.  
The signals controlling the switching of expression within the parasite are unclearly 
defined. Some evidences suggest that there is a communication between the host and the 
parasite and the homologous anti-variant antibody acts as a signal from host to parasite 
to induce switching (Brown, 1973). 
 
Introduction 
______________________________________________________________________________ 
 
 14 
1.10 Cytoadherence and its consequence on clinical manifestation 
P. falciparum is able to modify both of the membrane, cytoplasma and the surface of the 
infected erythrocytes (IE). By these modifications, the parasite is enabled to adhere to 
other host cells during trophozoite and schizont stages, called cytoadherence (Moxon et 
al., 2011). Three major types of cytoadherence have been described: sequestration if the 
IE adhere to endothelial cells (Udeinya et al., 1981), rosetting if IE bind to uninfected 
erythrocytes (Udomsangpetch et al., 1989) and auto-agglutination or clumping if the 
activated platelets bind with IE, forming a large cluster of cells (Pain et al., 2001). 
 
Sequestration 
P. falciparum-infected erythrocytes are found to be sequestered in various organs 
including brain, heart, lung, liver, kidney, sub-cutaneous tissues and placenta (Miller, 
1969; Yamada et al., 1989). Through successive cycles of sequestration and 
multiplication, parasites reach sufficient densities in micro-vascular beds to cause both 
organ specific and systemic disease. While sequestration is essential for the parasite’s 
survival by evasion of the spleen clearance mechanisms, it has severe consequences for 
the host. Parasite’s sequestration will occlude the capillary blood vessels, leading to 
hypoxia, metabolic acidosis and dysfunction of affected organs. Massive sequestration in 
the brain is believed as the underlying cause of coma in cerebral malaria, involving the 
role of host receptor intercellular adhesion molecule-1 (ICAM-1) (Chen et al., 2000). In 
addition, binding of IE to syncytiotrophoblasts resulting in placental sequestration 
occurs in pregnancy-associated malaria (PAM).  
 
Rosetting 
Another type of cytoadherence, the adhesion of IE to uninfected erythrocytes, is called 
rosetting. Rosetting has been observed in the peripheral blood of patients with acute 
severe malaria and in blood vessels during autopsy of malaria victims (Riganti et al., 
1990; Ho et al., 1991; Scholander et al., 1996). Some studies with largely different 
geographical and epidemiological setting also reported an association between rosetting 
forming capacity and disease severity (Carlson et al., 1990; Treutiger et al., 1992; Rowe et 
al., 1995; Udomsangpetch et al., 1996; Newbold at al., 1997; Kun et al., 1998; Heddini et 
al., 2001). Others reported that antibodies which disrupt rosettes are less common in 
individuals with clinical disease (Carlson et al., 1990; Reeder et al., 1997) and serum from 
severe malaria patients usually contains a low titer of anti-rosette antibodies, while 
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patients with uncomplicated malaria have a higher titer of anti-rosette antibodies 
(Barragan et al., 1998; Treutiger et al., 1992).  
Rosetting has a masking effect for IE. As the IE is in the middle and completely covered 
by uninfected erythrocytes, no antibodies or immune systems can recognize and 
eliminate the parasites. The aggregation of erythrocytes even enhances the negative 
effect of sequestration, because constricted capillaries due to sequestered IE, may be 
completely blocked by floating rosettes. In post-capillary venules, IE adhered to the 
endothelium and the uninfected erythrocytes formed rosettes on top of the adherent 
cells (Kaul et al., 1991), suggesting linked similar phenotypes between rosetting and 
sequestration. Some erythrocyte-rosetting receptors are also expressed on the endothelial 
cells, indicating a dual role in endothelial cytoadherence and rosetting (Vogt et al., 2003). 
This phenomenon is observed in the peripheral blood of patients with severe malaria 
and is thought to be an underlying cause of coma (Scholander et al., 1996). 
 
Auto-agglutination and clumping 
The ability of IE to adhere to neighbouring IE and thereby forming large aggregates 
without involving any uninfected erythrocytes is termed as auto-agglutination. This 
phenomenon is common in natural infections and a correlation with the disease severity 
has been shown (Roberts et al., 2000). Clumping is another adhesive phenomenon 
presented by IE, it is mediated by platelets and involved CD36 as a receptor adjoining IE 
to form large clumps (Wahlgren et al., 1995; Pain et al., 2001). Platelets serve as a bridge 
between CD36 and the surface of endothelial cells, providing receptors for adhesion to 
microvasular beds that otherwise lack adhesion receptors (Wassmer et al., 2004). 
However, not all CD36 binding isolates show this phenotype, indicating the involvement 
of other receptors. A platelet-mediated clumping varies between parasite isolates. Some 
studies reported a significant association of clumping with severe malaria (Pain et al., 
2001; Chotivanich et al., 2004; Wassmer et al., 2008). 
 
1.11 Host receptors involved in cytoadherence 
The affinity of P. falciparum for binding to endothelial cell receptors is diverse, as its role 
in sequestration and also depends on the host receptor specificity. Infected erythrocytes 
are able to bind to a range of host receptors with each parasite having the ability to bind 
a subset of them only.  
Numerous host receptors mediating binding to the IE have been identified. CD36 
(Barnwell et al., 1985; Ockenhouse et al., 1989), thrombospondin (TSP) (Roberts et al., 
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1985), intercellular adhesion molecule-1 (ICAM-1) (Berendt et al., 1989), platelet 
endothelial cell adhesion molecule-1 (PECAM-1/CD31) (Treutiger et al., 1997), vascular 
cell adhesion molecule-1 (VCAM-1), endothelial leukocyte adhesion molecule (ELAM) 
(Ockenhouse et al., 1992), E-selectin (Ockenhouse et al., 1992) and P-selectin 
(Udomsangpetch et al., 1997) are involved as receptors in the binding to endothelial 
cells. Chondroitin sulfate A (CSA) (Robert et al., 1995; Rogerson et al., 1995), hyaluronic 
acid (HA) (Beeson et al., 2000) and IgG (Flick et al., 2001) are the main receptors involved 
in sequestration in placental malaria.  
 
ICAM-1 
ICAM-1 is an 80-114 kDa glycosylated variabel membrane glycoprotein consisting of five 
Ig-like domains. It belongs to the immunoglobulin superfamily and is expressed on the 
surface of a wide range of cell types including endothelial cells and leukocytes (van de 
Stolpe and van der Saag, 1996; Ho et al., 2000). ICAM-1 is widely expressed on cerebral 
endothelium and leukocytes, and up-regulated by pro-inflammatory cytokines such as 
tumor necrosis factor (TNF-α). ICAM-1 has implicated to play a role in severe disease 
because the adhesion to ICAM-1 tended to be higher in patients with cerebral malaria 
(Newbold et al., 1997). In addition, there was a co-localization of ICAM-1 with parasite 
sequestration in brain vessels in autopsy samples from cerebral malaria patients (Turner 
et al., 1994). Further, up-regulation of ICAM-1 expression on endothelium during 
malaria infection was observed (Turner et al., 1998). 
A high frequency mutation in ICAM-1, called ICAM-1kilifi, was present in individuals 
from East and West Africa but absent in Europeans (Fernandez-Reyes et al., 1997). The 
studies on the effect of this mutation on susceptibility to severe malaria showed 
conflicting results. A study in Kenyan children found that homozygotes for this 
mutation were found to be at a two-fold higher risk of cerebral malaria than controls 
(Fernandez-Reyes et al., 1997), but another study in West Africa (Gambia and Gabon) 
reported the opposite association (Bellamy et al., 1998; Kun et al., 1999).  
Using a genome-wide approach, it was shown that only some PfEMP-1 variants 
containing the DBLβ-C2 domain are able to bind to ICAM-1 (Howell et al., 2008). The 
low affinity of most malaria parasites for this receptor indicates that ICAM-1 only 
mediates IE rolling on the endothelial lining; stable binding most likely occurs 
synergistically with other receptors such as CD36 (McCormic et al., 1997).  
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CD36 
CD36 is an 88-kDA glycoprotein scavenger receptor found on the surface of various cells 
including platelets, macrophages, monocytes, leukocytes, dendritic cells, epithelial cells 
and microvascular endothelial cells (Greenwalt et al., 1992). CD36 expression on cerebral 
endothelium of cerebral malaria patients was very little, but there was ubiquitously on 
lung, liver, kidney, skin and muscle vasculature (Turner et al., 1994; Turner et al., 1998). 
In contrast with ICAM-1 expression, CD36 and TSP are not sensitive to IFNγ or TNFα 
stimulation. Binding to CD36 and likewise to TSP seems to be a constitutive feature of 
most adherent parasite (Ockenhouse et al., 1991; Newbold et al., 1997), although binding 
to these receptors does not correlate with severity of disease (Turner et al., 1994; 
Newbold et al., 1997). 
 
Thrombospondin (TSP) 
TSP is an adhesive glycoprotein released into plasma in response to platelet activation 
by thrombin.  IE bind to purified TSP in static assays and bind to endothelial cells via 
TSP under flow conditions (Heddini et al., 2001; Roberts et al., 1985). A study 
investigating the association of TSP binding with severe malaria found that although 
most Kenyan field isolates adhered well to TSP in static assays, there was no correlation 
with disease severity (Heddini et al., 2001). 
 
P-selectin 
P-selectin (CD62P) is a glycoprotein that express on activated platelets and endothelial 
cells and is important for leukocyte trafficking. Studies in Thai field isolates showed that 
P-selectin mediates rolling of IE on endothelial cells and facilitates adhesion to CD36 
(Yipp et al., 2007; Udomsangpetch et al., 1997; Ho et al., 1998). 
 
PECAM-1/CD31 
PECAM-1/CD31 is widely expressed on endothelial cells, monocytes, platelets and 
granulocytes. IE bind to PECAM-1 on endothelial cells, and the binding site has been 
mapped to the first four immunoglobulin-like domains of PECAM-1. Parasite binding to 
PECAM-1 is up-regulated by IFN-γ. Although PECAM-1 binding parasites were almost 
as frequent as CD36-binding parasites in Kenyan isolates and parasites from patients 
with severe manifestation had a greater tendency to bind PECAM-1, the correlation with 
malaria severity was not significant (Heddini et al., 2001). 
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VCAM-1 (CD106) 
VCAM-1 is a member of the immunoglobulin superfamily and expressed by cytokine-
activated endothelium. Thai field isolates were shown to bind and roll on VCAM-1, but 
static adhesion did not occur. In African isolates, binding to VCAM-1 was extremely low 
and not associated with disease severity (Newbold et al., 1997). 
 
E-selectin (CD62E) 
E-selectin is a glycoprotein expressed on endothelial cells at sites of inflammation. In 
African isolates, E-selectin binding was extremely low and not associated with disease 
severity. The role of E-selectin in cytoadherence is thus probably minor (Newbold et al., 
1997). 
 
CSA and HA 
CSA and HA are especially well expressed on the surface of syncytiotrophoblast layer of 
the placenta. They mediate sequestration in pregnancy-associated malaria (PAM) 
(Beeson et al., 2000; Beeson et al., 1999; Maubert et al., 2000). Further, parasite binding to 
immunoglobulins may contribute to IE sequestration in the placenta. Immunglobulins 
act as a bridge between PfEMP-1 and the placenta, thereby assisted by CSA in placental 
adhesion (Flick, 2001; Rasti et al., 2006). Several studies have shown that parasite isolated 
from infected placenta typically adhere to CSA and/or HA but not to endothelial 
receptors such as ICAM-1 and CD36, and they do not form rosettes. Parasites isolated 
from children or non-pregnant adults, showed little or no adherence to CSA (Beeson et 
al., 1999).  
 
A number of different erythrocyte surface ligands are described to be involved in 
rosetting, including the blood group A and B antigens (Barragan et al., 2000), 
complement receptor 1 (CR1) (Rowe et al., 1997), heparan sulphate (HS) (Rogerson et al., 
1994; Rowe et al., 1994; Vogt et al., 2004), CD36 and glycosaminoglycans (GAGs) 
(Scholander et al., 1996; Chen et al., 1998; Handunnetti, 1989). All receptors are 
glycosylated, indicating that it is crucial for the interaction.  
 
A and B blood group antigens 
The A and B blood group sugars are trisacharides attached to a variety of erythrocyte 
glycoproteins and glycolipids, and are also found on platelets, leukocytes and 
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endothelial cells. All isolates tested showed a high preference for either A or B blood 
group erythrocytes (Udomsangpetch et al., 1993). Further, individual with blood A 
group antigen phenotype were more likely to suffer severe malarial disease and coma 
than those of other blood group (Fischer and Boone, 1998). Human genetic studies 
support a direct role of A- and B-mediated rosetting in the pathogenesis of severe 
malaria, because blood group O reduces rosetting in field isolates and confers significant 
protection against severe malaria (Rowe et al., 2007; Fry et al., 2008; Pathirana et al., 
2005). 
 
Complement Receptor 1 (CD35) 
CR1 is a complement regulatory protein and widely distributed on the surface of 
erythrocytes, leukocytes and dendritic cells (Khera and Das, 2009). It is an important 
rosetting receptor, since individual with CR1-deficiency was associated with protection 
from severe malaria (Cockburn et al., 2004). Some parasites cultured in CR1-deficient 
erythrocyte lose their capacity to form rosettes. Further, a monoclonal antibody against 
CR1 reverses rosetting, and deletion mutant of CR1 reverses rosetting in both laboratory 
and field strains (Rowe et al., 1997; Rowe et al., 2000).  
 
Heparan Sulphate (HS) and Glycosaminoglycan (GAG) 
Heparan sulphate (HS) and glycosaminoglycan (GAG) are involved in binding of 
rosetting IE to endothelial cells (Chen et al., 1998). The rosettes of most wild isolates can 
be disrupted by GAG, suggesting that malaria parasites use a GAG on the surface of 
erythrocyte as a rosetting receptor (Rogerson et al., 1994). GAG disrupts rosettes of 
FCR3S1 parasites and block rosette formation (Barragan et al., 1999). In a Kenyan field-
isolate study, binding of fluorescently labeled heparin was significantly higher in isolates 
from patients with severe malaria than those from uncomplicated disease, supporting a 
role of HS in severe malaria (Heddini et al., 2001). 
 
1.12 The role of PfEMP-1 in cytoadherence  
A lot of receptors have been described to be involved in cytoadherence in human hosts, 
but only few molecules from parasites have been proposed to serve as ligands for 
cellular adhesion. The best characterised molecule involved in cytoadherence is the 
PfEMP-1. PfEMP-1 is deposited on the surface of IE on knob-like structure from 
approximately 18 hours post invasion onwards. The interaction between PfEMP-1 with a 
large number of different host receptors requires several binding domains in the PfEMP-
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1 protein. The sequencing of var genes has enabled the mapping of specific receptor 
binding sites within PfEMP-1. There are several binding sites for numerous host 
receptors at the N-terminal of extracellular domain of PfEMP-1. 
 
DBL1α 
It is known that P. falciparum strain R29 binds CR1 on unifected erythrocytes via DBL1α 
domain to form rosettes (Rowe et al., 1997; Chen et al., 1998). The DBL1α domain also 
mediates heparin sulphate binding leading to sequestration. Binding residues for the 
CR1 lie in the central region of R29-DBL1α between conserved cysteine C5 and C12.  
A specific variant from a rosetting parasite clone binds to the blood group A trisacharide 
via the DBL1α domain to form rosettes (Chena et al., 2000). Although the majority of var 
genes appear to have a DBL1α domain, not all parasite isolates form rosettes or adhere 
to the receptors involved. It is important to stress that not all expressed var genes have 
the same binding properties and domain-specific binding varies considerably between 
var genes. 
 
CIDR1α 
CIDR1α is the domain mediating binding to CD36. Binding to CD36 is interesting as it is 
a feature of many parasite isolates (Ockenhouse et al., 1991, Newbold et al., 1997). 
Sequence analysis from diverse parasites corresponding to the CD36 binding region 
showed that CIDR1α sequences were not identical but displayed some homology, 
presented by a conservation of cysteine residues at the end of the fragment (Baruch et al., 
1997). 
An exception to CIDR1α-mediating binding to CD36 is an in vitro-selected CSA-binding 
parasite isolate, which revealed CSA-binding through a CIDR1α domain. As a 
consequence of binding to CSA through the same CIDR1α domain, CSA and CD36-
binding are mutually exclusive phenotypes (Gamain et al., 2002). In addition, CIDR1α 
together with DBL2δ domains of specific PfEMP-1 variants are thought to have binding 
capability to PECAM-1 (Chena et al., 2000). 
 
DBLβ-C2 
DBLβ-C2 is a PfEMP-1 domain mediating binding to ICAM-1. Binding residues for 
ICAM-1 lie in the central and terminal region of DBLβ-C2 domain between conserved 
cysteine C3 and C16 for ICAM-1 binding isolates ((Smitha et al., 2000; Mayor et al., 2005; 
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Springer et al., 2004). Alignment of ICAM-1 binding DBLβ-C2 domains from three 
isolates (A4, A4tres and JDP8) revealed significant homology sharing 16 conserved 
cysteine residues and a number of conserved hydrophobic amino acid residues, 
indicating conservation of the structure as well as three-dimensional structure. 
Furthermore, multiple sequence alignments of ICAM-1 binding and non binding DBL2β-
C2 domains suggested that the binding region for ICAM-1 is unlikely to lie in a linear 
sequence stretch within DBL2β-C2 (Chattopadhyay et al., 2004).  
 
DBLγ 
Although DBLγ domain has been linked to CSA binding, many expressed DBLγ domains 
do not bind CSA. One of the DBLγ domain binding CSA is expressed by the 
FCR3varCSA gene (Buffet et al., 1999). The binding residues for CSA from FCR3varCSA 
lie in the central region of DBLγ between cysteines 5 and 8 (Mayor et al., 2005). But, 
among those domains that bind CSA there are varying amounts both of homology and 
diversity in sequence without any clear conserved areas (Gamain et al., 2004). Of 
interest, var2CSA gene which is dominantly transcribed in many placental isolates and 
CSA-selected isolates, has an atypical structure lacking both DBLγ and CIDR1α domains 
instead possessing three DBLχ-type and three DBLε-type domains (Salanti et al., 2003). 
However, the role of var2CSA in CSA binding remains controversial, as the expression 
analysis of membrane proteins in placental and CSA-binding isolates showed that 
neither var2CSA nor FCR2varCSA were preferentially expressed on the surface of IE 
(Fried et al., 2004).  
Finally, the CD31/PECAM binding was reported to be mediated by CIDR1α, DBL2δ and 
the DBL5δ domain.  
The phenotype associations and both host receptors and P. falciparum ligands involved 
are summarized in table 1.1. 
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Tabel 1.1. Host cell receptors and P. falciparum ligands involved in cytoadherence. 
Host receptors Receptor location Parasite ligands 
(domain) 
Sequestration   
TSP Endothelium, serum PfEMP-1 
CD36 Endothelium, Erythrocyte PfEMP-1 (CIDR1α) 
ICAM-1 (CD54) Endothelium PfEMP-1 (DBLβ-C2) 
PECAM-1 (CD31) Endothelium, Monocyte PfEMP-1 (CIDR1α and 
DBL2δ) 
VCAM-1 (CD106) Endothelium ? 
ELAM-1 (E-selectin = CD62E) Endothelium ? 
P-selectin (CD62P) Endothelium, Platelet PfEMP-1 
CSA Endothelium PfEMP-1 (DBL3γ, CIDR1α) 
Rosetting   
A and B blood group Erythrocyte PfEMP-1 (DBL1α) 
CR1 (CD35) Erythrocyte PfEMP-1 (DBL1α) 
CD36 Erythrocyte, Endothelium PfEMP-1 (CIDR1α) 
HS Endothelial, aorta PfEMP-1 (DBL1α) 
GAG Erythrocyte PfEMP-1 (DBL1α) 
IgM and IgG Serum PfEMP-1 (CIDR1α, DBL2β) 
Clumping   
CD36 Platelet ? 
gC1qR/HABP1/p32 Platelet, Endothelium ? 
P-selectin Platelet ? 
 
 2. OBJECTIVES 
 
 
1. Analysis of P. falciparum var gene sequences from Indonesian’s field isolates 
Specific objectives of this topic: 
- To assess the overall diversity of P. falciparum var genes from Indonesian’s field 
isolates. 
- To identify an association of restricted motifs in the DBL1α domain with clinical 
outcome in malaria. 
- To investigate a potential association of transcribed specific genotypes of var 
genes with the manifestation of severe malaria. 
2. Analysis of P. falciparum DBLβ-C2 domains 
Specific objectives of this topic: 
- To explore the P. falciparum DBLβ-C2 sequences from Indonesian’s field isolates. 
- To construct recombinant pDBLβC2 domains from severe and uncomplicated 
malaria patients and assess the binding capacity of recombinant pDBLβC2 with 
ICAM-1. 
3. Detection of human P. knowlesi infection 
Specific objectives of this topic: 
- To identify naturally acquired human infections of P. knowlesi from Indonesian 
samples. 
- To investigate whether the available specific primers are sensitive and specific to 
diagnose P. knowlesi infection. 
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 3. MATERIALS AND METHODS 
 
3.1 Materials 
3.1.1 Study Site 
The study outlined in this thesis was carried out at the Saiful Anwar hospital, Malang, 
East Java province and Pelaihari district, South Kalimantan province, Indonesia (Figure 
3.1). The Saiful Anwar hospital serves as a referral hospital for the Eastern part of 
Indonesia, an area of moderate to high malaria endemicity. Most of the inpatient malaria 
cases in the Saiful Anwar hospital are imported cases from other areas such as Papua, 
Kalimantan or Nusa Tenggara, and the majority of patients suffered from severe malaria. 
Pelaihari district is located in South Kalimantan province, the region presents a range of 
different endemicity and environments, including coastal and hilly area with swamps 
and tropical climate. The climate is characterised by high temperature ranging between 
15.6°C and 26.9°C and heavy rainfall ranging between 75 mm and 426 mm annually, 
especially during October to May. Humidity ranges between 77% and 91%. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. P. falciparum malaria endemicity class in Indonesia (Elyazar et al., 2011). The 
blue dot shows the hospital where severe malaria patients were recruited. The circled 
areas are originated location of the samples: South Kalimantan and Papua province, the 
areas of moderate to high malaria endemicity in Indonesia.  
 
3.1.2 Sample collection 
Blood samples were collected from P. falciparum malaria patients. Patients were 
categorised as having either severe or uncomplicated malaria based on the clinical and 
laboratorical criteria of WHO for malaria disease.  
Materials and Methods 
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Inclusion criteria : 
1.    Patients age > 3 years old 
2. Patients body weight >13 kg 
3. Uncomplicated P. falciparum malaria: symptomatic malaria without signs of 
severity and/or evidence (clinical or laboratory) of vital organ dysfunction as 
found in severe malaria. 
• Parasite density <5%  
• Axillary temperature ≥ 37.5°C or recorded history of fever within the 
preceding 24 hrs 
• Symptoms: headache, lassitude, fatigue, abdominal discomfort, and muscle 
and joint aches, followed by fever, chills, perspiration, anorexia, vomiting and 
worsening malaise.  
4. Severe malaria: infection with P. falciparum with one or more of the following 
clinical symptom or laboratory test: 
• Coma (cerebral malaria) with abnormal behaviour, impairment of 
consciousness, seizures, coma, or other neurologic abnormalities 
• Prostration 
• Acute pulmonary oedema or acute respiratory distress syndrome (ARDS) 
• Circulatory collapse and shock, systolic blood pressure <70 mmHg in adult 
and <50 mmHg in children 
• Hepatic dysfuntion, clinical jaundice, bilirubin >3 mg% 
• Haemoglobinuria 
• Disseminated intravascular coagulation 
• Metabolic acidosis 
• Severe renal failure, creatinin >3mg% 
• Severe anaemia, haematocrit < 15% or Hb < 6g/dl 
• Hypoglycaemia, blood glucose < 40 mg/dl 
• Hyperparasitaemia > 5%  
5. Signed informed consent by the patient or the legal representative 
Exclusion criteria: 
1. Adequate anti-malarial treatment within previous 7 days 
2. Mixed plasmodial infection 
The study approved by Health Research Ethics Committee of the University of 
Brawijaya, Indonesia. Malaria patients were enrolled only after informed consent was 
Materials and Methods 
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signed. 
 
3.1.3 Reagents and Kits 
Reagent Company 
Acetic acid Merck, Darmstadt, Germany 
Ampicillin sodium-salt Sigma-Aldrich, Steinheim, Germany 
β-mercaptoethanol Sigma, Steinheim, Germany 
Big dye terminatorTM mix (V3.1) PE Applied Biosystem, CA, USA 
Bovine serum albumin (BSA) Sigma, Steinheim, Germany 
Chelex 100 Biorad, Munich, Germany 
d2H2O Millipore, Eschborn, Germany 
Deoxyribonuclease Invitrogen, Carslbad, USA 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Steinheim, Germany 
Dithiothreitol (DTT) Invitrogen, Carlsbad, CA, USA 
DMEM Gibco, Paisley, UK 
DNA ladder 1kb Invitrogen, Carlsbad, CA, USA 
DNA ladder 100 bp Invitrogen, Carlsbad, CA, USA 
DNase I Qiahen, Hilden, Germany 
dNTP mix (PCR grade) GeneAmp, Applied Biosystem, USA 
D-PBS Gibco, Paisley, UK 
Dye-Ex Spin kit Qiagen, Hilden, Germany 
Dynabeads M-280 Invitrogen, CA, USA 
Ethylenediaminetetraacetic acid (EDTA) Sigma, Steinheim, Germany 
Ethanol 70% Merck, Darmstadt, Germany 
Ethanol 96% Merck, Darmstadt, Germany 
Ethidium bromide Carl Roth, Karlsruhe, Germany 
Fetal bovine serum (FBS) Gibco, Paisley, UK 
Ficoll (type 400) Sigma, Steinheim, Germany 
Flow fix, 2% paraformaldehyde Polysciences, Eppelheim, Germany 
Fluoromount-G Southerbiotech, Birmingham, USA 
GelRed Nucleic acid stain 10.000x in water Biotium, Darmstadt, Germany 
Gentamycinsulphat Sigma-Aldrich, Steinheim, Germany 
Giemsa stain Sigma, Steinheim, Germany 
Glucose Merck, Darmstadt, Germany 
Glycerol Merck, Darmstadt, Germany 
HEPES (N-(2- Hydroxyethyl) piperazine-
N´- 2-ethanesulfonic acid) 
Sigma, Steinheim, Germany 
HiDi Formamide Applied Biosystem, Warrington, UK 
Hydrochloric acid (0.1 N) Merck, Darmstadt, Germany 
Hydrogen peroxide (H2O2) solution 35% Sigma, Steinheim, Germany 
Hypoxantine Sigma, Steinheim, Germany 
Isopropylthio-β-galactoside (IPTG) Invitrogen, CA, USA 
Isopropanol Carl Roth, Karlsruhe, Germany 
LB agar Sigma-Aldrich, Steinheim, Germany 
LB broth Sigma-Aldrich, Steinheim, Germany 
Lichrosolv water Merck, Darmstadt, Germany 
Lipofectin transfection reagent Invitrogen, CA, USA 
LongAmp Taq DNA polymerase NewEngland Biolabs, Schwalbach, Germany 
MgCl2 Sigma-Aldrich, Steinheim, Germany 
Methanol Merck, Darmstadt, Germany 
OligodT primer Invitrogen, CA, USA 
Opti-MEM reduced serum medium Gibco, Paisley, UK 
pGEM-T Easy vector Promega, Madison, USA 
Phenol/chloroform/isoamylalcohol 
(25:24:1) 
Merck, Darmstadt, Germany 
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Plasmid mini kit Qiagen, Hilden, Germany 
Polyethylenglycol (PEG) 4000 Merck, Darmstadt, Germany 
Potassium acetate Sigma, Steinheim, Germany 
Qiamp DNA blood mini kit Qiagen, Hilden, Germany 
Qiamp RNA blood mini kit Qiagen, Hilden, Germany 
Qiashredder column kit Qiagen, Hilden, Germany 
QuickLyse miniprep kit Qiagen, Hilden, Germany 
Random hexamer primer p(dN)6 Invitrogen, CA, USA 
Restriction enzymes MBI Fermentas, St Leon-Rot, Germany 
Restriction enzymes NewEngland Biolabs, Schwalbach, Germany 
RNeasy mini kit Qiagen, Hilden, Germany 
RPMI 1640 Sigma-Aldrich, Steinheim, Germany 
SOC medium NewEngland Biolabs, Schwalbach, Germany 
SeaKem agarose Cambrex Bio Science Rockland, USA 
Sodium chloride (NaCl) Merck, Darmstadt, Germany 
Sodium hydroxide (NaOH) Merck, Darmstadt, Germany 
Superscript II reverse transcriptase Invitrogen, CA, USA 
T4 DNA ligase Invitrogen, CA, USA 
Taq DNA polymerase MP Biomedical, Germany 
Tris (2-hydroxymethyl-aminomethan) GE health care, Biosciences AB, Uppsala, 
Sweden 
Triton-X Carl Roth, Karlsruhe, Germany 
Tryple express, stable trypsin Gibco, Paisley, UK 
Trypan blue Sigma Aldrich, Steinheim, Germany 
Tween 20 Merck, Hohenbrunn, Germany 
Ultrafree-DA extraction kit Millipore, Karlsruhe, Germany 
Whatman filter paper GE Health care, England 
X-gal (5-Bromo-4-Chloro-3-indolyl a-
Dgalactopyranoside) 
Invitrogen, CA, USA 
 
3.1.4 Sundry Materials 
Material Company 
Cell Culture well Corning, USA 
Coverslip EMS, USA 
Cryotube vials Nalge Nunc, Thermo scientific, Denmark 
Centrifuge tubes Corning, Mexico 
Filter units Millipore, Belford, USA 
Inoculation loop, sterile Greiner bio-one, Frickenhausen, Germany 
Microcentrifuge tubes Eppendorf, Hamburg, Germany 
Microscope slide Menzel-Gläser, Thermo scientific, 
Braunschweig, Germany 
Needle B. Braun, Emmenbruecke, Germany 
Petridishes Nunc, Thermo scientific, Germany 
Pipette tips Kisker, Steinfurt, Germany 
Syringe B. Braun, Emmenbruecke, Germany 
Strypette Corning, USA 
Surgical scalpels Aesculap, B.Braun, Tuttlingen, Germany 
Tissue culture flasks TPP, Switzerland 
 
3.1.5 Buffers and Solutions 
Buffers and solutions used in molecular biology 
Name Components 
5x DNA Ligase reaction buffer 250 mM Tris-HCl pH 7.6 
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(Supplied with T4 DNA Ligase) 50 mM 
5 mM 
5 mM 
25 % 
MgCl2 
ATP 
DTT 
PEG 8000 
Storage : -20oC 
1x Tango buffer (Restriction 
enzyme buffer), Fermentas 
33 mM 
10 mM 
66 mM 
0.1 
mg/ml 
Tris-acetate pH 7.9 
Mg acetate 
Potassium acetate 
BSA 
Storage: -20oC 
1x NE Buffer 4 50 mM 
20 mM 
10 mM 
1 mM 
Potassium acetate 
Tris-acetate 
Mg acetate 
DTT 
pH 7.9 at 25oC 
Storage: -20oC 
1x LongAmp Taq reaction buffer 60 mM 
20 mM 
2 mM 
3% 
0.06% 
0.05% 
Tris-SO4 
(NH4)2SO4 
MgSO4 
Glycerol 
NP-40 
Tween-20 
Storage: -20oC 
1x PCR buffer with Mg 10 mM 
50 mM 
1.5 mM 
0.1% 
0.2mg/
ml 
Tris-HCl 
KCl 
MgCl2 
Triton X100 
BSA 
Storage: -20oC 
Buffer for plasmid preparation 
Solution I (resuspend buffer) 
 
50 mM 
25 mM 
10 mM  
 
Glucose 
Tris-HCl pH 8.0 
EDTA pH 8.0 
Storage : 2-8 oC 
Solution II (lysis buffer) 1 % 
0.2 N 
SDS 
NaOH 
Storage : 15-25 oC 
Solution III (neutralization buffer) 10 M 
5 M 
Potassium acetate pH 4.8 
Acetic acid 
Storage : 15-25 oC 
10x TAE (Tris-acetate-EDTA) 
buffer 
0.4 M 
0.2 M 
10 mM 
Tris 
Acetic acid 
EDTA 
pH 8.3 
Storage : 20oC 
10x TAE buffer was purchased from 
Carl Roth, Karlsruhe, Germany 
10x TAE buffer light 0.4 M 
1 mM 
Tris-acetate 
EDTA 
pH 8.3 
Storage : 20oC 
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10x TAE buffer light was purchased 
from Carl Roth, Karlsruhe, Germany 
10x BlueJuice Gel Loading buffer 65 % 
10 mM 
10 mM 
0.3 % 
Sucrose 
Tris-HCl pH 7.5 
EDTA 
Bromophenol blue 
Storage : 4 oC 
TE (Tris-EDTA) buffer 10 mM 
1 mM 
Tris-HCl 
EDTA pH 7.5, Autoclave 
Storage : RT 
 
Buffers and solutions used in cell culture and immunofluorescence assay 
Name Components 
Freezing medium 10% 
90% 
DMSO 
DMEM + 10% FBS 
Binding medium 0.5 % 
25 mM 
BSA 
HEPES 
In RPMI 1640 pH 7.0 
 
3.1.6 Equipments 
Instrument Company 
Centrifuge EBA 12 Hettich zentrifugen, Germany 
Centrifuge Rotina 46 Hettich zentrifugen, Germany 
Centrifuge mikro 22R Hettich zentrifugen, Germany 
Centrifuge Biofuge Pico Heraeus, Germany 
Fluorescence microscope Axioskop Carl Zeiss, Goettingen, Germany 
DNA analyzer ABI 3730 Applied Biosystems, CA, USA 
Fridge 4oC Liebherr, Germany 
Freezer -20oC Liebherr, Germany 
Freezer -80 oC Sanyo 
Horizontal gel electrophoresis system Peqlab Biotechnologie, Erlangen, Germany 
Incubator Heraeus, Germany 
Inverted microscope Leitz Labovert, Germany 
Laminar flow Aura 2000 MAC Bio Air Instruments S.r.l, Pavia, Italy 
Liquid nitrogen tank Air liquide Kryotechnik, Dusseldorf, Germany 
Mini cenrifuge MCF-2360 LMS, Japan 
Neubauer counting chamber Marienfeld Superior, Lauda-Koenigshofen, Germany 
pH meter Sartorius, Germany 
Phase-contrast microscope Zeiss, Germany 
Qubit fluorometer Invitrogen, USA 
Thermocycler T professional Biometra, Goettingen, Germany 
Thermomixer HLC MHL 20 HLC, Mannhein , Germany 
UV transilluminator Bachofer, Reutlingen, Germany 
UV transilluminator UVP, Cambridge, England 
Vortex IKA MS3 basic IKA, USA 
Waterbath  Memmert, Germany 
Waterbath Julabo, Germany 
 
3.1.7 Softwares 
Name Company Usage 
Adobe Photoshop CS2 Adobe System Inc. Image processing 
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BioEdit v7.1.3 Tom Hall, Ibis 
Biosciences, Abbott 
laboratory, CA, USA 
Analysis DNA sequences 
DNASis Max v3.0 MiraBio Group, Hitachi 
Solution America, Ltd. 
Analysis of DNA, RNA and amino 
acid sequences 
EndNote X4 Thompson ISI, CA, USA Bibliography management 
Expasy translate tool Expasy Bioinformatics 
Resource, Swiss Institute 
of Bioinformatics 
Translation of DNA sequences into 
amino acid sequences 
Grab-IT Ultra Violet Product 
(UVP) Ltd, Cambridge, 
UK 
Annotating image capture system 
MS Office Microsoft Corporation, 
USA 
Text editing, data analysis and 
graph generation 
NCBI-BLAST National Library of 
Medicine, Bethesda, MD 
Running and interpreting BLAST 
sequence comparison 
Sequence scanner v1.0 Applied Biosystem, USA View, edit, print and export data 
generated using the Genetic 
Analyzer 
VarDom 1.0 server Center for Biological 
Sequence analysis (CBS), 
Denmark 
Composition and classification 
analysis of the malaria antigen 
family PfEMP-1 
 
3.1.8 Culture medium 
3.1.8.1 Parasite culture media 
Incomplete medium: 
10.43 g RPMI 1640 powder 
2.00 g Glucose 
0.05 g Gentamycin sulfate 
5.94 g HEPES 
0.04 g Hypoxanthine  
Add distilled water to 1 liter, and adjust pH to 7.2. Filter-sterilized and store at -
20°C. 
Complete medium: 
97.2 ml Incomplete medium 
2.8 ml NaHCO3 (7.5%)  
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11-22 mL of human sera (inactivated at 56°C for 60 min, then stored at -20°C). The 
amount of serum depends on the age of the culture, in the first week medium 
should contain 20% serum, with the increasing stabilily of the culture, sera can be 
reduced to 10%.  
5% erthrocyte suspension: 
5 ml Packed cells 
 95 ml Complete medium 
 
3.1.8.2 Bacterial culture media 
LB medium: 
1 % Tryptone 
0.5 % yeast extract 
0.5 % NaCl 
1.5 % agar (for plates only) 
pH 7.0 
A ready to use mixture of the above components for LB-broth or LB-agar was used from 
Sigma. An appropriate amount of the powder was dissolved in d2H2O and autoclaved. 
In order to select transformants, ampicillin was added to the medium at final 
concentration of 50 µg/ml. The LB-agar medium with antibiotic was poured into 
Petridish and stored at 4°C. 
 
3.1.8.3 Cell culture media 
Complete medium: Dulbecco’s Modified Eagle Medium (DMEM) + 10% FBS. 
 
3.1.9 Bacterial strains 
Bacterial 
strain 
Genotype Company 
E. coli DH5α F- φ80lacZ∆Μ15 ∆(lacZYA-argF)U169 recA1 end A1 
hsdR17(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1λ- 
Invitrogen, USA 
 
E. coli JM109 endA1, recA1, gyrA96, thi, hsdR17 (rK-, mK+), relA1, 
supE44, ∆(lac-proAB), [F’, traD36, proAB, 
lacIqZ∆M15] 
Promega, USA 
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3.1.10 Mammalian cell line 
COS-7 cells are immortalised fibroblast-like kidney cells from African green monkeys. 
This cell line is appropriate for transfection by vectors requiring expression of SV40 T 
antigen. It contains T antigen, retains complete permissiveness for lytic growth of SV40, 
supports the replication of ts A209 virus at 40°C and supports the replication of pure 
populations of mutants with deletions in the early region. The line was derived from the 
CV-1 cells (ATCC CCL 70) by transformation with an origin-defective mutant of SV40 
which codes for wild type T antigen. 
ATCC Number: CRL-1651 
ECACC Number: 87021302 
 
3.1.11 Plasmids 
Name Company Usage 
pGEM-T 
Easy 
Promega, 
Madison, USA 
Cloning vector with a single 3’-T overhangs at the 
cloning site for direct cloning of PCR products. It has 
α-peptide coding region of the enzyme β-
galactosidase within the cloning region to allow 
identification of recombinant by blue/white 
screening. 
pUC19 Invitrogen, USA Cloning vector, used as transformation control. 
pRE4 Prof. Gary Cohen 
and Prof. Roselyn 
Eisenberg, 
University of 
Pennsylvania, 
USA 
Expression vector contains a SV40 ori, a Rous 
sarcoma virus LTR (RSV LTR) and the SV40polyA. It 
has the HSV glycoprotein D (HSV gD) used as the 
signal sequence and hydrophobic transmembrane to 
target different regions of the malarial erythrocyte 
binding proteins to the surface of mammalian cells. 
 
3.1.12 Primers 
Species-specific primers for Plasmodium spp. 
1. rPLU5 5’-CCT GTT GTT GCC TTA AAC TTC-3’ 
2. rPLU6 5’-TTA AAA TTG TTG CAG TTA AAA CG-3’ 
3. rFAL1 5’-TTA AAC TGG TTT GGG AAA ACC AAA TAT ATT-3’ 
4. rFAL2 5’-ACA CAA TGA ACT CAA TCA TGA CTA CCC GTC-3’ 
5. rVIV1 5’-CGC TTC TAG CTT AAT CCA CAT AAC TGA TA-3’ 
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6. rVIV2 5’-ACT TCC AAG CCG AAG CAA AGA AAG TCC TTA-3’ 
7. rMAL1 5’-ATA ACA TAG TTG TAC GTT AAG AAT AAC CGC-3’ 
8. rMAL2 5’-AAA ATT CCC ATG CAT AAA AAA TTA TAC AAA-3’ 
9. rOVA1 5’-ATC TCT TTT GCT ATT TTT TAG TAT TGG AGA-3’ 
10. rOVA2 5’-GGA AAA GGA CAC ATT AAT TGT ATC CTA GTG-3’ 
11. Pmk8 5’-GTT AGC GAG AGC CAC AAA AAA GCG AAT-3’ 
12. Pmkr9 5’-ACT CAA AGT AAC AAA ATC TTC CGT A-3’ 
 
P. falciparum genotyping primers 
13. M1-OF 5’-CTA GAA GCT TTA GAA GAT GCA GTA TTG-3’ 
14. M1-OR 5’-CTT AAA TAG TAT TCT AAT TCA AGT GGA TCA-3’ 
15. M1-KF 5’-AAA TGA AGA AGA AAT TAC TAC AAA AGG TGC-3’ 
16. M1-KR 5’-GCT TGC ATC AGC TGG AGG GCT TGG ACC AGA-3’ 
17. M1-MF 5’-AAA TGA AGG AAC AAG TCG AAC AGC TGT TAC-3’ 
18. M1-MR 5’-ATC TGA AGG ATT TGT ACG TCT TGA ATT ACC-3’ 
19. M1-RF 5’-TAA AGG ATG GAC CAA ATA CTC AAG TTG TTG-3’ 
20. M1-RR 5’-CAT CTG AAG GAT TTG CAG CAC CTG GAG ATC-3’ 
21. M2-OF 5’-ATG AAG GTA ATT AAA ACA TTG TCT ATT ATA-3’ 
22. M2-OR 5’-CTT TGT TAC CAT CGG TAC ATT CTT-3’ 
23. M2-ICF 5’-AGA AGT ATG GCA GAA AGT AAK CCT YCT ACT-3’ 
24. M2-ICR 5’-GAT TGT AAT TCG GGG GAT TCA GTT TGT TCG-3’ 
25. M2-FCF 5’-AAT ACT AAG AGT GTA GGT GCA RAT GCT CCA-3’ 
26. M2-FCR 5’-TTT TAT TTG GTGBCAT TGC CAG AAC TTG AAC-3’ 
27. G-OF 5’-TGA ATT TGA AGA TGT TCA CAC TGA AC-3’ 
28. G-OR 5’-GTG GAA TTG CTT TTT CTT CAA CAC TAA-3’ 
29. G-NF 5’-TGT TCA CAC TGA ACA ATT AGA TTT AGA TCA-3’ 
 
Universal var primer to amplify the DBL1α 
30. αAF 5’-GCA CG(A/C) AGT TTT GC-3’ 
31. αBR 5’-GCC CAT TC(G/C) TCG AAC CA-3’ 
 
 Specific primer for var D-like gene 
32. var-DF 5’-AAT TCC T(C/G)A TGA (A/T)TT TAA (G/A)CG-3’ 
33. var-DR 5’-CAC ATA ACA T(T/C)C C(A/T)T TCC A-3’ 
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Primer pair to amplify conserved DBL domain 
34. UNIEBP-5 5’-CC(A/G) AG(A/G) AG(A/G) CAA (G/A)AA (C/T)TA TG-3’ 
35. UNIEBP-3 5’-CCA (A/T)C(T/G) (T/G)A(A/G) (A/G)AA TTG (A/T)GG-3’ 
 
Sequencing primers for pGEMT-Easy vector 
36. SP6 5'-ATT TAG GTG ACA CTA TAG AAT AC-3' 
37. T7 5’-TAA TAC GAC TCA CTA TAG GGC GA-3’ 
 
Primer pair to amplify the whole DBLβ-C2 domain 
38. DBL2F1 5’-AGT GTG TTG AAG GAC GTA TGT-3’ 
39. DBL2R3 5’-CCA AAC ATA TAT CTC TAT AAT CTC C-3’ 
 
Specific primer walking to sequence DBLβ-C2 domain 
40. DBLSeq_F 5’-ATG ACT GAA TGG GC(C/A) GAA TG-3’ 
41. DBLSeq_R1 5’-CAA GAA GTC ATA CAC GGA T-3’ 
42. DBLSeq_R2 5’-TAG TAC CAC CGA TTG AGC GT-3’ 
43. DBLSeq_R4 5’-TAC ATT CTG GAT CCT CTT C-3’ 
44. DBLSeq_R5 5’-TGT TCA TCG TCT TCA CCT T-3’ 
45. DBLSeq_R11a 5’-CGTTGACTTGTGTACCACCA-3’ 
46. DBLSeq_R11b 5’-ATG CGT CCT TAT ACT CTG G-3’ 
 
Specific primer to amplify the ICAM-1 binding portion of DBLβ-C2 domain 
47. DBL2_ICAM_F 5’-TCT CGT CAG CTG AGT GTG TTG AAG GAC GTA-3’ 
48. DBL2_ICAM_R 5’-ACG AGT GGG CCC C(C/A)A AAG TTC TTT AAC 
TAT-3’ 
49. DBL2_ICAM_R1 5’-ACG AGT GGG CCC ATT TGT GAC TAT AGT GCA-3’ 
50. DBL2_ICAM_R4 5’-ACG AGT GGG CCC TCC TTC CAC AGT TTT ACA-3’ 
51. DBL2_ICAM_R5 5’-ACG AGT GGG CCC AAG CAT TTT GTC CAC CGT-3’ 
52. DBL2_ICAM_R11 5’-ACG AGT GGG CCC AAC TAT TTT GCA GGC AGG-3’ 
 
3.1.13 Antibodies 
Antibody Company Working 
dilution 
Dynabeads M-280 Sheep anti- Invitrogen, USA 1-2x107 
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mouse IgG beads/ml 
DL6 monoclonal antibodies 
(mouse) 
Prof. Gary Cohen and Prof. Roselyn 
Eisenberg, University of Pennsylvania, 
USA 
1:2000 
Fluorescein-conjugated goat 
anti-mouse antibodies 
Jackson ImmunoResearch, USA 1:100 
ID3 monoclonal antibodies 
(mouse) 
Prof. Gary Cohen and Prof Roselyn 
Eisenberg, University of Pennsylvania, 
USA 
1:2000 
Mouse anti-human IgG Fc 
gamma fragment antisera 
Jackson ImmunoResearch, USA 0.1-1µg 
Abs/beads 
Recombinant human ICAM-
1/CD54 Fc chimera 
R and D System, Wiesbaden, Germany 1.5-2x106 
beads 
 
3.2 Methods 
3.2.1 Cultivation of fresh Plasmodium falciparum isolates from patients 
A sample of parasitized erythrocytes was collected from severe and asymptomatic or 
uncomplicated malaria patients. Blood was collected into tube containing heparin and 
saved at 4oC until processed. Blood were layered by Ficoll and separated by 
centrifugation at 2000 rpm for 5 min. Erythrocytes were collected and washed three 
times in RPMI 1640. The isolates were grown in complete medium and supplemented 
with 5% erythrocyte suspension. Cultures were maintained at 37oC in an atmosphere of 
94% nitrogen, 5% carbon dioxide and 1% oxygen, and the culture medium is changed 
every day. The growth rate was monitored by microscopic examination of Giemsa-
stained smears.  
 
Sorbitol-synchronization of P. falciparum culture 
The parasite culture was harvested at the ring stage (10-12 h post invasion culture). The 
culture was centrifuged at 1200 rpm for 2 min, the pellet were added with the same 
volume of 5% sorbitol and incubated for 10 min at RT, with 2 or 3 times shaking. The 
culture was centrifuged, washed 3 times in complete medium and diluted to 5% 
erythrocyte suspension. The culture was counted and subcultured. 
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3.2.2 Microbiology techniques 
3.2.2.1 Bacterial cultures 
The frozen cells from the glycerol stocks or resuspension of lyophilized cells were 
streaked out on to LB-agar plates containing appropriate selective antibiotics and 
incubated o/n (over-night) at 37°C to obtain single colonies. A single colony was then 
inoculated in the LB medium containing appropriate antibiotic and incubated o/n at 
37°C in a shaking incubator at 250 rpm. To prepare competent bacterial cells, LB agar 
and medium without antibiotics were used. 
 
3.2.2.2 Preparation of bacterial stocks 
850 µl of an overnight bacterial culture was mixed with 150 µl sterilized glycerol and 
store at -80oC for long term storage. 
 
3.2.2.3 Preparation of chemically competent bacteria 
A single bacterial colony was inoculated in 50-100 ml of LB medium and incubated at 
37°C with shaking at 250 rpm. The culture was grown until the cell density reached an 
OD600 of 0.4-0.5, it took for approximately 3-6 hours. In order to stop the bacterial 
growth, the cultures were put on ice immediately. The cells were harvested by 
centrifugation at 2500 xg for 15 min at 4°C and resuspended in 1/10 volume (5-10 ml) of 
ice cold TSS and place on ice. The competent cells were aliquoted (50-100 µl vol.) and 
stored at -80°C. 
For some cloning experiments, highly efficient chemically competent E. coli DH5α cells 
and E. coli JM109 cells were purchased from invitrogen and promega, respectively. 
 
3.2.3 Molecular biology techniques 
3.2.3.1 DNA extraction 
DNA extraction from patients whole blood and P. falciparum culture 
Genomic DNA was isolated from whole blood of malaria patients and parasite culture 
by QIAamp DNA Blood mini kit (Qiagen) according the manufacture’s instruction. 200 
µl of whole blood or of harvested uniformly ring-stage parasite culture by centrifugation 
at 300 xg for 5 min was diluted with 200 µl PBS, then added with 20 µl proteinase-K. The 
mixture were added with 200 µl buffer AL, vortexed for 15 s and incubated at 56oC for 10 
min. The samples were precipitated with 200 µl ethanol 96-100% and applied to the 
QIAamp Mini spin column to centrifuge at 8000 rpm for 1 min. Then added with 500 µl 
buffer AW1 and centrifuged at 8000 rpm for 1 min. The procedure was continued by 
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adding the sample with 500 µl buffer AW2 and centrifuged at full speed for 3 min. 
Finally, the samples were dissolved by adding 200 µl buffer AE and centrifuging at 8000 
rpm for 1 min. DNA was stored at -20oC. 
 
DNA extraction from blood on filter paper 
DNA extraction from blood on filter paper was conducted using Chelex boiling method. 
Chelex was gently mixed by magnetic stirer for 10 min before used. The blood spot on 
filter paper was cut for approximately 1 cm2 and put into 1.5 ml tube. The sample was 
dissolved with 200 µl prepared Chelex and mixed well by vortexing for 30 sec. The 
sample was cooked by heating at 100oC for 15 min and centrifuged at 12.000 rpm for 2-5 
min. The supernatant was collected and centrifuged at 12.000 rpm for 2-5 min. 80-100 µl 
of supernatant was collected and stored at -20oC. 
 
3.2.3.2 RNA extraction 
RNA extraction from patients whole blood and P. falciparum culture 
Total RNA was isolated from whole blood and parasite culture using QIAamp RNA 
blood mini kit according to the manufacturer’s protocol. 500 µl of whole blood or 
harvested synchronized parasite culture by centrifugation at 300 xg for 5 min was mixed 
with 5 volume of buffer EL and incubated on ice for 10-15 min. The sample was 
centrifuged at 400 xg at 4oC for 10 min and the supernatant was discarded. The sample 
was lysed again by adding 2 volume of buffer EL and centrifuged, and added 350 µl of 
buffer RLT to the pellet before applied to the QIAshredder spin column and centrifuged 
at maximum speed for 2 min. The sample was added with 1 volume of 70% ethanol and 
applied to the QIAamp spin column and centrifuged for 15 sec at >10000 rpm. The 
sample was washed with 700 µl buffer RW1 and added with 500 µl buffer RPE and 
centrifuged for 15 sec >10000 rpm, and once again with 500 µl of buffer RPE, centrifuged 
at maximum speed for 3 min. Finally RNA was diluted with 30-50 µl of RNase-free 
water and centrifuged for 1 min at >10000 rpm. RNA was used immediately or stored at 
-80oC. 
 
RNA extraction from blood on filter paper 
RNA was also extracted from dried blood on filter paper using RNeasy Mini Kit 
(Qiagen). The blood spot was cut for approximately 0.3 cm2 and placed into the tube. 600 
µl of RLT buffer was added and incubated in thermomixer at 1000 rpm 37oC for 30 min. 
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The lysate was applied to the QIA shredder spin column and centrifuged at 13.000 rpm 
for 2 min. 1 volume of 70% ethanol was added to the homogenized lysate and mixed 
properly by pipetting. 700 µl of lysate was applied to the RNeasy spin column and 
centrifuged for 15 sec at >10.000 rpm. The sample was washed by adding 350 µl of buffer 
RW1 to the column and centrifuged for 15 sec at >10000 rpm. 10 µl DNase I stock 
solution was mixed with 70 µl buffer RDD and the mix solution was applied to the spin 
column membrane and incubated at RT for 15 min. The column was washed again with 
350 µl buffer RW1 and centrifuged at >10000 rpm for 15 sec. The sample was added with 
500 µl buffer RPE, centrifuged for 2 min at >10000 rpm and centrifuged once again at 
maximum speed for 1 min. Finally diluted RNA by adding 30-50 µl of RNase-free water 
directly to spin column membrane and centrifuging for 1 min at >10000 rpm. RNA was 
used immediately or stored at -80oC. 
 
3.2.3.3  cDNA synthesis 
A complementary DNA (cDNA) is a DNA copy synthesized from RNA. cDNA synthesis 
is used to determine the level of gene expression. cDNA is synthesized first using 
oligodT or random primers in the present of four deoxynucleotide triphosphates (dNTP) 
by using reverse transcriptase with RNA or mRNA as a template reaction, followed by 
PCR.  
RNA was treated with DNase I for 15 min at 37oC to avoid contamination with genomic 
DNA. The mixture contained of 1ng-5µg total RNA, 1 µl of 500µg/ml OligodT primer 
and 1 µl dNTP mix (10mM each) was heated to 65oC for 5 min and quick chilled on ice. 
4µl of 5x first-strand buffer and 2 µl of 0.1 M DTT was added to the mixture and 
incubated at 42oC for 2 min. The mixture was then reverse transcribed using 1 µl (200 U) 
of Superscript II RT by incubating at 42oC for 50 min and the reaction were inactivated 
by heating at 70oC for 15 min. The cDNA was used as a template for subsequent PCR 
and stored at -20oC. 
 
3.2.3.4 Polymerase Chain Reaction (PCR) 
The PCR is a technique for amplifying a piece of DNA of interest in an exponential 
manner. The amplification requires synthetic oligonucleotides, so called primers, which 
flanking the target sequence to be amplified. These primers, under appropriate 
conditions, anneal to the denatured target sequence and, in the presence of a heat stable 
DNA polymerase enzyme and dNTPs, direct synthesis a complementary strand of the 
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target sequence. As a template 1 µl cDNA (10-200 ng) or 1 µl genomic DNA (0.1-1 µg) or 
0.5 ng plasmid DNA were used. The PCR reactions were prepared as follows: 
 
PCR component Amount (µl) 
20 µl per reaction 
Final concentration 
10x PCR buffer 2.0 1x 
25 mM MgCl2 1.2 – 2.0 1.5 – 2.5 mM 
10 mM dNTP mix 0.4 200 µM 
10 µM forward primer 0.4 – 1.0 0.2 – 0.5 µM 
10 µM reverse primer 0.4 – 1.0 0.2 – 0.5 µM 
DNA template (0.5 ng/µl to 1 µg/µl) 1 - 5 N.A 
DNA polymerase (5U/µl) 0.2 – 0.3 1 – 1.5 U 
ddH2O Adjust to 20  
 
Some reactions were also performed in 50 µl. And the cycle conditions were as follows: 
 
Step Temperature (oC) Duration (min:sec) No. of cycles 
Initial denaturation 94-95 4:00 1 
Denaturation 94-95 0:45 - 0:60 
Annealing 42-65 0:60 
Extension 65-72 1:00 - 3:00 
 
25 - 35 
Final extension 65-72 10:00 1 
 
The annealing temperatures are varied between 42 and 65oC depend on the length and 
Tm (melting temperature) of the primer pairs, it should be 5oC below the lowest Tm of 
the pair of primers. The extension temperatures depend on the DNA polymerase used, 
and the duration of extension varied according to the length of the target sequence with 
the rule of 1 min per 1000 bp fragment. 
 
Plasmodium species-specific identification by PCR 
Species-specific identification was conducted with nested PCR. All PCR amplifications 
were carried out in a 20 µl reaction mixture: 
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PCR component Amount (µl) Final concentration 
10x PCR buffer + MgCl2 (1.5 mM) 2.0 1x 
100 mM dNTP mix 0.1 500 µM 
10 µM forward + reverse primer 0.5 0.25 µM/primer 
DNA template (0.5ng/µl to 1 µg/µl) 1.0 N.A 
DNA polymerase (5U/µl) (MP 
Biomedical) 
0.08 0.4 U 
ddH2O Adjust to 20  
 
The amplification was performed in a thermocycler (Biometra, Germany) as follows: 
 
Step Temperature (oC) Duration (min:sec) No. of cycles 
Initial denaturation 95 5:00 1 
Denaturation 94 1:00 
Annealing 58 2:00 
Extension 72 2:00 
 
25 
Final extension 72 5:00 1 
 
DNA of P. falciparum, P. malariae, P. vivax, P. ovale and P. knowlesi were included as 
positive controls. One microliter of the nested 1 amplification product served as DNA 
template of each of the 20 µl nested 2 amplification. Another components of the reaction 
mixture were identical with nested 1. Nested 2 amplification conditions were identical to 
those of nested 1 except for P. knowlesi which used the annealing temperature of 60oC 
and 30 cycles.  
 
3.2.3.5 DNA analysis and purification 
Determination of DNA/RNA concentration 
DNA concentration was measured using Qubit Fluorometer, fluorescence-based dyes 
that bind specifically to DNA, RNA and protein. The purity of the sample was 
determined by the OD260/280 ratio. The pure DNA sample should have a ratio between 
1.8 and 2.0. Smaller ratios usually indicate contamination by protein or organic 
chemicals. 
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Agarose gel electrophoresis 
Agarose gel electrophoresis was applied for DNA separation. It is used for both analysis 
and isolation of the DNA fragments. The concentration of agarose gel was determined 
according to the desired range of separation of DNA fragment. Higher concentrations 
facilitate separation of small DNAs, while low agarose concentrations allow resolution of 
larger DNA fragment, as shown in the table below:  
 
% agarose Range of separation for linear DNA 
0.5 1 – 30 kb 
0.7 0.8 – 12 kb 
1.0 0.5 – 10 kb 
1.2 0.4 – 7 kb 
1.5 0.2 – 3 kb 
2.0 0.05 – 2 kb 
 
The gel was prepared by boiling the desired concentration of agarose in 1x TAE buffer. 
After cooled to approximately 50oC, 1 µl of GelRed Nucleic acid stain was added per 10 
ml of gel volume. The gel was poured onto a horizontal gel-tray and waited until 
completely cooled before transferred into appropriate gel chamber. 8-10 µl DNA samples 
or DNA marker were loaded in the gel slots with loading dye added to 1x final 
concentration. The DNA fragments were separated by applying an electrical field 60-100 
V, under these condition the negatively charged DNA molecules would migrate to the 
anode at rates that are inversely proportional to the length of the individual DNA 
fragments. Larger molecules migrate slower than smaller molecules. The gels would 
typically be run for 1-2 hours. The detection was done using UV light transilluminator 
(302 nm), and the gels were documented using Grab-IT program. 
 
DNA purification from agarose gel 
DNA fragments that would be used in the cloning experiments or directly sequencing 
were cut out from the gels and extracted from the gel using Ultrafree_DA extraction kit 
(Millipore) according to the manufacturer’s instruction. The excised gel slice was 
transferred to the column and centrifuged at 5000 rcf for 10 min. The DNA was stored at 
-20oC. 
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3.2.3.6 DNA digestion using restriction enzymes 
Restriction endonuclease cuts the DNA at a short specific nucleotide recognition site. For 
site-specific digestion of DNA, type II restriction endonucleases are required. The 
enzymes are able to recognize, bind and cleave the phosphodiester bond at short specific 
nucleotide sequence within DNA target. The digestion of DNA was performed with 
specific buffers that had a various compositions of salts and buffering agents depending 
on the restriction enzyme used. When double digest were applied, an appropriate buffer 
for both enzymes were used according to the manufacturer’s instruction. For single 
digestion the following components were mixed and the digestion was allowed for 1 
hour at enzyme-dependent temperature: 
 
Reaction component Amount 
Appropriate enzyme Buffer 1x final concentration 
Restriction enzyme 5 - 10 units 
DNA 0.5 - 1µg 
Nuclease free-water To a final volume of 50 µl 
 
3.2.3.7 Ligation 
Ligation reactions were performed to ligate the DNA fragments from vector and insert 
(PCR products). The ligation reactions of PCR products with pGEMT-Easy vector were 
performed according to the manual. The vector and insert were used at a molar ratio of 
1:1 to 1:3 (vector : insert) in the ligation reaction as described in the following table. The 
reaction was incubated o/n at 4oC or 1-2 hours at RT. 
 
Reaction component Amount (µl) 
2x Rapid Ligation buffer 5 
pGEMT-Easy vector (3 kb in size; 50 ng) 1 
Insert DNA (0.5 kb in size) x 
T4 DNA Ligase (3 U/µl) 1 
Nuclease-free water Adjust to 10 
 
3.2.3.8 Transformation of plasmid DNA into bacterial cells 
The transformation was performed according to the manufacturer’s instuctions. Briefly, 
the competent cells were thawed on ice for 5-10 min. 5 µl control DNA (50 pg) was 
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pipetted in a pre-chilled tube containing 100 µl competent cells and 2-3 µl ligation 
reaction in 50 µl competent cells, mixed by gentle flicking. The mixtures were incubated 
on ice for 30 minutes, heat-shocked in 42°C water bath for 45 sec and immediately 
chilled on ice for 2 min. The transformed cells were resuspended in pre-warmed SOC 
medium to a volume of 1 ml. The cultures were incubated at 37°C with 250 rpm shaking 
for 60-90 min, then 100-200 µl transformation reaction was plated on LB agar containing 
ampicillin, IPTG and X-gal. The plates were incubated o/n at 37°C. 
 
3.2.3.9 Plasmid DNA isolation 
Plasmid DNA was isolated from bacteria using the alkaline lysis method (Sambrook, 
1989). Some plasmid mini preparation kits (Qiagen plasmid mini kit) were also 
purchased. The plasmid isolation was performed according to the manufacturer’s 
instructions. A single white E. coli colony was inoculated into 3 ml of LB medium 
containing selective antibiotic and incubated at 37°C with vigorous shaking for 
approximately 8 hours. The starter cultures were diluted 1/500 to 1/1000 into 3 ml 
selective LB medium and incubated at 37°C with vigorous shaking for 12-16 hours. The 
cultures were harvested by centrifugation for 15 min at 8000 rpm and the supernatant 
was discarded. The pellet was resuspended in 300 µl of P1 buffer and the cells were 
lysed by adding 300 µl of P2 buffer and incubated at RT for 5 min. The lysate was 
neutralized with 300 µl of P3 buffer and incubated on ice for 5 min. The reaction was 
centrifuged at maximum speed for 10 min and the supernatant containing plasmid DNA 
was applied to a Qiagen-tip. The Qiagen-tip was washed with the buffer QC and DNA 
was eluted with the buffer QF. The DNA was precipitated with 0.7 volume of RT 
isopropanol, mixed and centrifuged at >10.000 rpm for 30 min. The DNA pellet was 
washed with 1 ml of 70% ethanol and centrifuged at 10.000 rpm for 10 min. The pellet 
DNA was air-dried, dissolved in 50µl of TE buffer and stored at -20oC. 
 
3.2.3.10 Sequencing 
DNA sequencing was applied to confirm the identity of a clone and obtain the exact 
sequence. For all sequencing, the Sanger chain termination method was used. The 
sequencing was performed with a cycle-sequencing dye-dideoxy chain termination 
protocol. The cycle sequencing reaction consists of successive rounds of denaturation, 
annealing and extension in the presence of primer, DNA polymerase, dNTPs and dye-
labeled terminator dideoxy nucleotides (ddNTPs). For the cycle sequencing reaction, the 
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following components were added:  
 
Reaction component Amount (µl) 
Sequencing buffer 1.5 
BigDye terminator v3.1 0.5 
Primer (10 µM) 1 
PCR product or plasmid DNA 10-100 ng PCR product or 0.5-1.0 µg plasmid DNA 
 
The reaction was performed in a thermocycler with the following program: 
 
Step Temperature (oC) Duration (min:sec) No. of cycles 
Denaturation 96 00:30 
Annealing 50 00:15 
Extension 60 04:00 
 
25 
 
After completed cycle sequencing, 15 µl ddH2O was added to reach a volume of 20 µl. 
This mixture was cleaned-up using a DyeEx 2.0 spin column (DyeEx 2.0 spin kit, Qiagen) 
and centrifuged at 2700 rpm for 3 min according to the manufacturer’s instructions. This 
step efficiently removes the excess dye terminators from the completed DNA sequencing 
reactions. The purified sequencing reaction was then precipitated with 3 volume of 
ethanol 96% and twice with 2 volume of ethanol 70%. All precipitation reactions were 
carried out by centrifugation at maximum speed (in g or rpm) for 3 min. After drying for 
approximately 45 min, the samples were diluted with 12 µl HiDi Formamide plus 13 µl 
Lichrosolv water and loaded in a 96-well sample plate of a DNA Analyzer (ABI 3730, 
Applied Biosystems) for sequence analysis. 
 
3.2.3.11 Sequence analysis 
The nucleotide sequences were aligned using BioEdit program and DNASIS MAX 
version 3.0 and analyzed for sequence similarities by NCBI BLAST 
(http://www.ncbi.nlm.nih.gov/Blast.cgi). The nucleotide sequences were translated 
into amino acid sequences using Expasy Translation Tool 
(http://www.expasy.ch/tools/dna.html). The multiple sequences were aligned using 
ClustalW alignment. Percentage sequence similarity test and phylogenetic tree analysis 
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were carried out using the algorithm in DNASIS MAX version 3.0 based upon a 
ClustalW alignment. 
 
3.2.4 Cell culture techniques 
3.2.4.1 Cultivation of mammalian cells 
The mammalian cell line (COS-7 cells) were grown in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and incubated in a 
37oC incubator containing a humidified atmosfer of 5% CO2. For harvesting the adherent 
cells, the 80-100% confluent cultures were washed with D-PBS and treated with pre-
warmed Trypsin-EDTA for 5 min to detach the cells from the surface of culture flask and 
separate the cells from each other. The activity of the trypsin was stopped by adding 
complete medium (DMEM+10%FBS) and the cells suspension was either used for 
subculturing or for the preparation of frozen stocks. The cell lines were propagated and 
maintained by seeding at the density of 1-2 x 104 viable cells/cm2 every 3-5 days 
depending on the growth characteristic of the cells. 
 
3.2.4.2 Freezing and thawing of mammalian cells 
Mammalian cell lines can be maintained by storing them in liquid nitrogen.  For 
freezing, 80-100% confluent culture were pelleted by centrifugation at 100 x g for 5 min 
and resuspended in chilled freezing medium containing complete medium and 10% 
volume of DMSO to reach approximately 5 x 106 viable cells/ml. The cells suspension 
were transferred into cryo tubes and then put  in a -80°C freezer to cool the cells about -
1°C/min. After 24 hrs, they can be stored in liquid nitrogen. 
The frozen cells can be revived by proper thawing. For optimal recovery, rapid thawing 
was important, therefore the cells were thawed rapidly in a 37°C waterbath and washed 
with 10-20 ml D-PBS or culture medium and centrifuged at 1000 rpm for 5 min. The 
pellet was resuspended in fresh pre-warmed DMEM supplemented with 10% FBS. The 
cell lines were cultured for a minimum of 3 passages before used in other experiments. 
 
3.2.4.3 Determination of cell viability 
To determinate cell viability, we used trypan blue exclusion assay. Trypan blue stain 
distinguishes viable cells from non-viable cells by their capability to absorb the dye, 
viable cells actively exclude the trypan blue while non-viable cells absorb dye. For 
counting the number of viable cells, the cell suspension was diluted with trypan blue at a 
ratio of 1:1 to 1:9 (cell suspension:trypan blue) and the number of viable cells in a 4 x 1 
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mm2 area (4 x 100 nl? µl? of diluted cell suspension) were counted with the help of a 
Neubauer haemocytometer under a phase contrast microscope. The total number of 
viable cell per ml of the cell suspension was calculated using the following formula: 
 
 
3.2.4.4 Transient transfection of adherent cells 
Transient transfections of adherent cells were performed by using a transfection reagent 
(Lipofectin, Invitrogen). One day before transfection, COS-7 cells were plated into 
coverslip in six-well plates with 2 ml DMEM supplemented with 10% FBS. The cells 
were incubated for 16-24 hours in a humidified 5%-CO2 atmosphere at 37°C until 60-80% 
of the well bottom was covered by cells. 3-5 µg of plasmid DNA was diluted with 100 µl 
OPTI-MEM reduced serum and mixed with the dilution of 10 µl lipofectin in 100 µl 
OPTI-MEM reduced serum, then incubated for 15 min at RT. Meanwhile, the cells were 
washed once with 2 ml DMEM without serum. The DNA-complex were added with 800 
µl OPTI-MEM without serum and added to the cells and incubated at 37°C in a CO2 
incubator for 5-24 hours. The medium was replaced with 2 ml complete growth medium 
(DMEM+10% FBS). The transfected cells were assayed for expression and binding 
activity by immunofluorescence assay after 24-72 hours post transfection. 
 
3.2.5 Immunofluorescence techniques 
3.2.5.1 Immunofluorescence assay to test transfection efficiency and expression of 
construct on the surface of COS-7 cells 
The transfected COS-7 cells were washed twice with PBS and fixed in 2% 
paraformaldehyde for 15 min in RT then washed again in PBS. The fixative cells were 
stained with the primary antibody (ID3 or DL6) at a dilution of 1:2000 in PBS containing 
0.1% BSA for 1 hour at RT. The cells were washed with PBS for 10 min and incubated 
with fluorescein-conjugated goat anti-mouse antibodies (Jackson Immunoresearch 
Laboratory) at a dilution of 1:100 in PBS containing 0.1% BSA for 1 hour. The cells were 
washed again with PBS for 10 min, mounted with Fluoromount (Southern Biotechnology 
Associates Inc) and air dried for 5 minutes before examination. The surface expression 
was scored using a fluorescence microscope. The mAbs (ID3 or DL6) were tested against 
untransfected COS-7 cells to check for the background fluorescence.  
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3.2.5.2 Immunofluorescence assay to assess the ICAM-1 binding of the recombinant 
construct pDBLβ-C2 
Coating Dynabead M-280 sheep anti-mouse IgG with ICAM-1 
Dynabeads M-280 sheep anti-mouse Ig G antibody (Invitrogen) were washed before use 
to remove preservatives, facilitated by the use of a magnet as recommended by 
manufacturer. The Dynabeads M-280 were resuspended thoroughly in the vial by 
vortexing and transfered the required amount of resuspended beads into a new tube. 
The tube was placed on the magnet for 2 min and pipetted off the supernatant. After 
removing the tube from the magnet, the pellet was resuspended in an excess volume of 
washing buffer (0.1% bovine serum albumin in PBS). The tube was placed again on the 
magnet, pipetted off the supernatant and resuspended the washed beads in any 
choosing volume of washing buffer with the final concentration of 1-2 x 107 beads/ml.  
Washed Sheep anti-mouse Ig G antibody-coated magnetic Dynabeads were incubated 
with mouse anti-human IgG Fc gamma fragment antisera (Jackson ImmunoResearch) at 
a concentration of 0.1-1.0µg antibody/107 beads. Beads were mixed by rotation for 3 h at 
RT. The tube containing the mixture was placed on the magnet for 2 min and pipetted 
off the supernatant, than removed from the magnet and washed with washing buffer. 
The tube was placed again on the magnet, removed the supernatant and washed with 
washing buffer. After coating with mouse anti-human IgG Fc gamma fragment antisera, 
the beads were than coated with recombinant ICAM-1/Fc protein (R&D Systems) at 
ratio of 1.0µg ICAM-1/107 beads (per 1 x 106 cells), or mock treated for controls by 
overnight incubation. The beads were washed with washing buffer and resuspended in 
binding medium (0.5% bovine serum albumin, 25 mM HEPES in RPMI-1640 pH 7.0) at a 
concentration of 3.7 x 107 beads/ml and warmed to 37oC prior to adding the cells. 
 
Assessing binding of recombinant construct pDBLβ-C2 with ICAM-1 coated beads 
Binding of recombinant construct pDBLβ-C2 with ICAM-1 coated beads was tested at 
pH 7.0. Two days (40-60 h) post-transfection, transfected COS-7 cells in coverslips were 
transferred to an empty fresh well of six-well plate (Falcon) and overlaid with 40 µl of 
binding medium (0.5% BSA, 25mM HEPES in RPMI 1640) containing 1.5 – 2.0 x 106 
beads of ICAM-1-coated or mock-coated. The cells were incubated in a humidified 
container for 1 h at 37°C and filled with 10 ml of binding medium at the same pH used 
during the incubation of beads and cells (pH 7.0). The coverslips were then flipped cell-
side down onto a stand and incubated for 5 – 10 min to allow unbound beads to settle by 
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gravity. Coverslips were then returned to cell-side up and examined under phase 
microscopy to determine the degree of beads association.  
To prove that beads specifically associated with transfected cells, coverslips were fixed 
in 2% paraformaldehyde (Polysciences) for 15 min at RT. The fixed coverslips were 
processed for immunofluorescence as previously described (2.2.5.1) to analyze the 
coincidence of recombinant protein expression and bead association. 
Binding was expressed as a percentage of transfected cells containing five or more 
ICAM-1 coated beads. Experiments were carried out in duplicate with a minimum of 50 
transfected cells were analyzed for each construct. Standard deviation was calculated 
using Microsoft excel (Springer et al., 2004). 
 
3.2.6 Statistical analysis 
Standard statistical analysis (eg. mean, median and standard deviation) was calculated 
using the built in statistic functions of Microsoft Excel program. The differences between 
sequence groups were analyzed using Fisher’s Exact and Chi-square tests. All tests were 
two-tailed and results considered significant if p<0.05 meaning that there is a 95% 
chance that the two groups being compared would be truly different if looking at the 
entire population of parasites. 
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 4. RESULTS 
 
4.1 Characteristic of samples 
Twelve Indonesian malaria patients with written informed consent were enrolled in this 
study. All patients were adults, five suffered from clinically severe malaria and seven 
were uncomplicated malaria. Severe patients were hospitalised in the Saiful Anwar 
hospital in Malang who came either from Papua or South Kalimantan province. 
Uncomplicated cases were recruited from Pelaihari district, South Kalimantan. All 
severe cases had an impairment of consciousness along with one or more severe clinical 
manifestations defined by WHO including severe anaemia, respiratory distress, renal 
failure, hepatic dysfunction and jaundice. One patient was pregnant in the third 
trimester, the case was considered as a pregnancy-associated malaria (PAM). Patients 
had symptoms up to 14 days before they were recruited. Patients were microscopically 
diagnosed as mono-infection of P. falciparum, severe malaria patients had parasitaemia 
ranging between 1% and 24.6%, parasitaemia of uncomplicated cases ranged between 
0.2% and 2% (Table 4.1). 
 
Table 4.1. Profile of malaria patients 
Sex Age 
(years) 
Origin Parasitae
mia (%) 
Disease state group 
Severe malaria 
M 35 Papua 10 Cerebral malaria, anaemia, 
respiratory distress, renal 
failure 
M 50 South Kalimantan 1 Cerebral malaria, clinical 
jaundice, anaemia 
F 19 Papua 12.8 Cerebral malaria, clinical 
jaundice, severe anemia, 
PAM 
M 47 South Kalimantan 2 Cerebral malaria, anaemia 
M 51 Papua 24.6 Cerebral malaria, clinical 
jaundice, renal failure, 
hepatic dysfunction 
Uncomplicated malaria 
M 35 South Kalimantan 1.1 Mild malaria 
M 41 South Kalimantan 0.2 Mild malaria 
M 19 South Kalimantan 1 Mild malaria 
M 54 South Kalimantan 1 Mild malaria 
M 16 South Kalimantan 1 Mild malaria 
M 35 South Kalimantan 1 Mild malaria 
M 55 South Kalimantan 2 Mild malaria 
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4.2 Identification of Plasmodium species 
In order to molecularly confirm mono-infection of P. falciparum, Plasmodium species-
specific PCR was conducted by using specific primers of five different Plasmodium spp 
causing human malaria (3.1.12). Eight out of twelve patients were detected as mono-
infection with P. falciparum, three samples were mixed infection with P. falciparum, P. 
vivax and P. knowlesi, and one sample was mixed infection of P. vivax and P. knowlesi. 
Neither P. malariae nor P. ovale were detected in the samples. Due to the inclusion 
criteria, we excluded the samples with mixed-infections. Only eight samples of P. 
falciparum mono-infection were included in the further analysis.  
 
4.3 Detection of human Plasmodium knowlesi case 
Because of the origin of the samples, they were examined for P. knowlesi, the proposed 
fifth humanpathogenic Plasmodium. Amplification by using specific primer Pmk8 and 
Pmkr9 (3.1.12), designed for P. knowlesi-specific DNA sequences on the small subunit 
ribosomal RNA (ssrRNA) gene, yielded a single band of 153 bp in four samples (Figure 
4.1). All P. knowlesi-positive samples were mixed infection with P. vivax and/or P. 
falciparum. None of them were positive in the P. malariae specific PCR. They had 
clinically mild malaria with a low range of parasitaemia between 0.2% and 1% and were 
microscopically diagnosed as mono-infection of P. falciparum (Table 4.2). P. knowlesi-
positive samples came from South Kalimantan province, the Indonesian part of Borneo, 
none from Papua. 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Amplification results using Pmk8 and Pmkr9 primers to detect P. knowlesi 
case. Four positive samples numbered as 1 to 4 generated a 153 bp band. M: marker 100 
bp, C+: positive control, C-: negative control. 
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Table 4.2. Profile of Plasmodium knowlesi-positive patients 
Sex Age 
(years) 
Clinically Microscopy
-base 
diagnosis 
PCR-base 
diagnosis 
Sequence analysis 
of P. knowlesi  
153 bp band 
M 35 Mild 
malaria 
P. falciparum P. falciparum,  
P. vivax, P. knowlesi 
P. vivax 
M 41 Mild 
malaria 
P. falciparum P. falciparum,  
P. vivax, P. knowlesi 
P. vivax 
M 54 Mild 
malaria 
P. falciparum P. falciparum,  
P. vivax, P. knowlesi 
P. vivax 
M 16 Mild 
malaria 
P. falciparum P. vivax, P. knowlesi P. knowlesi 
(GU233448) 
 
PCR using P. knowlesi-specific primers (Pmk8 and Pmkr9) yielded a single band of 153 
bp and direct sequencing of the PCR products were performed. Sequencing showed a 
perfect matching with the recently published P. knowlesi S-type from Malaysian Borneo 
and Vietnam in one of the four samples (Figure 4.2). The other sequences were 
repeatedly consistent with the ssrRNA gene of the P. vivax S-type, blasting results 
presented higher homology (93-100%) with various P. vivax strains than with different P. 
knowlesi (maximum of 82% homology) or other Plasmodia strains 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Multiple alignment of P. knowlesi ssRNA from Indonesia with other P. 
knowlesi strains. Indonesian P. knowlesi sequence showed a 99-100% homology with P. 
knowlesi S-type from Malaysia and Vietnam. Compared to P. knowlesi Nuri strain S-type, 
there was only one nucleotide ‘T’ deletion in 127 bp. 
 
4.4 Genotyping of Plasmodium falciparum 
P. falciparum-mono infection samples were genotyped using the highly polymorphic 
repetitive regions of MSP-1, MSP-2 and GLURP genes. Multiple fragments were detected 
from all allelic families (Table 4.3). Ten different bands in the MAD20 allelic family were 
found, 0-4 in each sample; the fragment size ranged from near 160 bp to approximately 
P.know_Ind
P.know_Vietnam_FJ871986
P.know_KH43 S-type_DQ350257
P.know_Nuri strain S-type_DQ350263
P.know_Ind
P.know_Vietnam_FJ871986
P.know_KH43 S-type_DQ350257
P.know_Nuri strain S-type_DQ350263
P.know_Ind
P.know_Vietnam_FJ871986
P.know_KH43 S-type_DQ350257
P.know_Nuri strain S-type_DQ350263
10 20 30 40 50
GTTAGCGAGA GCCACAAAAA AGCGAATTCC AATATATGTT TTCTGCTTTA
GTTAGCGAGA GCCACAAAAA AGCGAATTCC AATATATGTT TTCTGCTTTA
GTTAGCGAGA GCCACAAAAA AGCGAATTCC AATATATGTT TTCTGCTTTA
GTTAGCGAGA GCCACAAAAA AGCGAATTCC AATATATGTT TTCTGCTTTA
60 70 80 90 100
TGTGCGCATC CTCTACCTAT TAAGTGTTAA TTAAATTAAA GGGTTTCTTT
TGTGCGCATC CTCTACCTAT TAAGTGTTAA TTAAATTAAA GGGTTTCTTT
TGTGCGCATC CTCTACCTAT TAAGTGTTAA TTAAATTAAA GGGTTTCTTT
TGTGCGCATC CTCTACCTAT TAAGTGTTAA TTAAATTAAA GGGTTTCTTT
110 120 130 140 150
TTAAAATCTT CTATAACTAA TAAAAA-ATA CGGAAGATTT TGTTACTTTG
TTAAAATCTT CTATAACTAA TAAAAA-ATA CGGAAGATTT TGTTACTTTG
TTAAAATCTT CTATAACTAA TAAAAA-ATA TGGAAGATTT TGTTACTTTG
TTAAAATCTT CTATAACTAA TAAAAATATA TGGAAGATTT TGTTACTTTG
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350 bp. The K1 allelic family showed four bands between 180 bp and 350 bp, each 
sample presented maximum two. The RO33 allelic family showed two fragments of 
approximately 160 bp and 180 bp solely in two samples (Kal1 and Kal3). By using MSP-2 
genotyping, six different bands of the 3D7/IC family were detected, 0-4 in each sample 
ranging from approximately 400 bp to 800 bp. The FC27 family presented ten different 
bands, ranging from 270 bp to 600 bp, 0-6 per sample. 1–2 bands in each sample were 
observed by using GLURP specific primers with seven different bands between 600 bp 
and 1.1 kb. Amplified bands of MSP-1, MSP-2 and GLURP presenting a similar fragment 
size were considered clonally identical.  
The multiplicity of infection (MOI), which is defined as the minimum number of 
genetically different parasite lines (clones) present in each sample was calculated by 
counting the number of bands observed for each genetic markers of three distinct 
families of MSP-1 and two distinct families of MSP-2, and the highest number between 
two genetic markers is considered as the MOI of the sample. The MOI of samples were 
in a range of 2 and 10 parasite lines for each sample where the samples from severe cases 
tended to have a higher MOI (4-10 parasite lines) than samples from uncomplicated 
cases (2-3 parasite lines). 
 
Table 4.3. Genotyping results by MSP-1, MSP-2, and GLURP 
Number of MSP-1 
bands 
Number of 
MSP-2 bands 
Sample Malaria 
clinical 
MAD
20 
K1 RO33 3D7/IC FC27 
Number 
of 
GLURP 
bands 
MOI
* 
Pap1 Severe 4 2 0 1 4 1 6 
Kal1 Severe 1 0 1 2 2 2 4 
Pap2 Severe 4 2 0 3 0 1 6 
Kal2 Severe 3 2 0 1 6 1 7 
Pap3 Severe 4 1 0 4 6 2 10 
Kal3 Uncomplicated 0 1 1 1 1 1 2 
Kal4 Uncomplicated 2 0 0 0 2 2 2 
Kal5 Uncomplicated 1 1 0 1 2 1 3 
 
*MOI = multiplicity of infection is defined as the minimum number of genetically 
different parasite lines (clones) present in each sample. 
MOI was calculated by counting the number of variants (bands) observed for each of 
genetic markers, for MSP-1 the bands observed for the MAD20, K1 and RO33 families 
are added and for MSP-2 the bands detected for the 3D7/IC and FC27 are added. The 
highest number between two genetic markers is considered as the MOI of the sample. 
Results 
______________________________________________________________________________ 
 55
4.5 Diversity of var genes 
var genes diversity was determined by amplification of both genomic DNA and cDNA 
using universal primer αAF and αBR (3.1.12). The design of the primers was based on 
the high conservation in flanking regions of DBL1α, the amino-terminal DBL domain. 
Since the DBL1α is present in most family members of the var gene, the primer pair 
amplifies the majority of var gene repertoire in both laboratory and field isolates. 
Amplification resulted a single fragment of ∼370 - 450 bp in each sample both from 
genomic DNA and cDNA (Figure 4.3). Amplified bands were then cloned into cloning 
vector pGEMT-Easy to allow identification of every single DBL1α sequence within 
amplified fragments. It was attempted to characterise the majority of DBL1α sequences 
from each sample. Sequencing was conducted twice for each clone from both strands 
using SP6 and T7 primers located within the vector. 
(a) 
 
(b) 
 
 
 
 
 
 
 
 
 
Figure 4.3. Amplification results of universal primer αAF and αBR. Each sample 
generated a single band of ∼370–450 bp; (a) Amplification fragment from genomic DNA. 
(b) Amplified band of cDNA synthesised from RNA of blood on filter paper; C_Pos: 
positive control; C_Neg: negative control. 
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Derived from eight field isolates, where three originated from Papua and five from 
South Kalimantan province, seventy-one different sequences out of total 104 DBL1α 
sequenced clones were identified with less than 95% sequence similarity. Twelve 
different sequences derived from parasite cDNA of four severe and one of 
uncomplicated malaria patients. Others were amplified from parasite genomic DNA of 
all patients. On average, 8.9 different DBL1α sequences per isolate were discovered. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Unrooted phylogram of DBL1α sequence tag from Indonesian field isolates 
and other global isolates. Four pairs (Kal4.C62 - Kal5.C1; Kal4.B12 - Kal5.A4, Kal1.B7 - 
Kal5.C3; Pap2.A2 - Pap3.A11) of DBL1α sequences presented more than 95% similarity. 
Each pair was detected in two different isolates but originated from the same 
geographical area. Two sequences from Papua (Pap1.13 and Pap3.C8) showed more than 
95% similarity with isolates from India and Solomon Islands. 
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The average DBL1α amino acid sequence similarity within isolates ranged from 47.2 + 
6.8 to 51.8 + 5.9 and among isolates from 42.4 + 6.5 to 49.4 + 6.8. Four pairs of DBL1α 
sequences presenting more than 95% similarity were detected, where three pairs were 
found in the two isolates from Kalimantan (Kal4.C62 and Kal5.C1; Kal4.B12 and Kal5.A4; 
Kal1.B7 and Kal5.C3) and one similar sequence was observed in Pap2.A2 and Pap3.A11 
from Papua isolates. In comparison with published sequences, only two sequences from 
Papua (Pap1.13 and Pap3.C8) showed more than 95% similarity with isolates from India 
and Solomon Islands, respectively. Phylogenetic analysis demonstrated no clustering of 
sequences regarding strain or geographical origin (Figure 4.4). 
 
4.6 Determination of distribution motif in DBL1α 
4.6.1 Classification of the DBL1α sequence tag 
The DBL1α sequence tag regions start at a DIGDI motif within homology block (HB) ‘d’ 
and end at a PQFLR motif within HB ‘h’ of the Smith’s classification (2000b). The 
sequence tags are classified into six sequence groups based on the number of cysteine 
residues within the tag region and a set of sequence motifs at four positions of limited 
variability (PoLV1-4) as proposed by Bull et al. (2007). The positions within the 
sequences are fixed in relation to four anchor points. PoLV1 and PoLV4 are defined in 
relation to the 5’ and the 3’ ends of the sequence, respectively. PoLV2 and PoLV3 are 
correlated to a “WW” motif. This classification is referred to as a cysteine/PoLV 
sequence grouping and described as follows: 
-  Group 1: cys2, PoLV1(MFK*) 
-  Group 2: cys2, PoLV2(*REY) 
-  Group 3: cys2 not groups 1, 2 
-  Group 4: cys4 not group 5 
-  Group 5: cys4, PoLV2(*REY) 
-  Group 6: cys1, 3, 5, >5 
The DBL1α sequences were also characterised by recently described homology blocks 
(HB)s using the VarDom 1.0 server (http://www.cbs.dtu.dk/services/VarDom/), a 
server dedicated particularly to analyse composition and classification of the malaria 
antigen family PfEMP-1. Homology Block is defined as a member of sequences with 
similarity to the sequence profile above a certain threshold (9.97) as determined by Rask 
and colleagues (2010). This HB classifications are also redefined the Smith’s HB a-j 
classification, where HBb=HB4, HBd=HB3, HBf=HB5, HBh=HB2 and HBj=HB1, but 
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based on the similarity threshold, the remaining Smith’s HB are not found to be 
conserved in all DBL classes.  
 
4.6.2 Sequence distribution motif of DBL1α 
Analysis of DBL1α sequence showed a conservation of certain residues in DBL1α 
domain. The conserved regions were interspersed within variable blocks and vary in 
both length and sequence. A cysteine/PoLV sequence classification presented a similar 
distribution of all sequence groups between isolates causing severe and uncomplicated 
malaria (p=0.48), but all sequences of group 3 were obtained from severe cases. 
Comparison of the individual sequence groups demonstrated that there was strong 
evidence for a difference between sequence group 3 and group 4 (p=0.02) and between 
sequence group 3 and group 6 (p=0.03). Sequence group 4 which has 4 cysteine residues, 
termed as a normal number of cysteine within DBL1α sequence tag, was identified as the 
most frequent sequence in both severe and uncomplicated malaria patients (Figure 4.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Distribution of DBL1α sequences into six sequence groups according to the 
clinical presentation. Parasite isolates from both severe and uncomplicated malaria 
patients showed a similar distribution of DBL1α sequence, with a notification that all 
sequences group 3 were obtained from severe cases. The majority of sequences from 
both clinical cases belong to sequence group 4. 
 
In addition, analysis of DBL1α sequence tag in association with the geographical origin 
by using the cysteine/PoLV sequence grouping indicated no evidence for a specific 
difference between isolates from Papua and South Kalimantan province (p=0.18). 
Similar to the report by Bull et al. (2007) concerning the association between PoLV motifs 
and distinct sequence length distributions, sequences containing the MFK* at PoLV1 
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(group 1) or the *REY at PoLV2 (group 2 and 5) were associated with short sequences 
(Figure 4.6).  
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Association of PoLV motifs with distinct sequence length distributions. 
Two PoLV motifs were independently associated with short sequence i.e. MFK* at 
PoLV1 for sequence group 1 and *REY at PoLV2 for sequence group 2 and 5. 
 
(a)      (b) 
 
 
 
 
 
 
 
 
(c)      (d) 
 
 
 
 
 
 
 
Figure 4.7. Distribution of PoLV1-4 motifs within isolates causing severe and 
uncomplicated malaria. Each PoLV has one motif as a major motif that was observed in 
both severe and uncomplicated cases. Some motifs were detected solely in severe or 
uncomplicated malaria. (a) The most frequent motif of PoLV1 was LYLG. (b) In PoLV2 , 
LRED was the major motif. (c) Most PoLV3 motifs were KAIT. (d) Main motif in PoLV4 
was PTYF.  
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One motif in each PoLV was revealed as the major motif and observed in both severe 
and uncomplicated cases, i.e. LYLG in PoLV1, LRED in PoLV2, KAIT in PoLV3 and 
PTYF in PoLV4. Some motifs were detected solely in either severe or uncomplicated 
malaria (Figure 4.7).  
Analysis using varDom server showed that our DBL1α sequences stretched from the 
most prevalent HB3 to HB2, including subdomain S2b and S2c. It showed a presence of 
HB36 in all sequences containing 4 cysteine residues (cys4) but absence in all sequences 
containing 2 cysteine residues (cys2) as described previously (Rask et al., 2010). HB60 
was found in almost all cys2 sequences and in 11 of 51 (21.6%) cys4 sequences. The same 
percentage of cys4 sequences presented also HB88 that were absent in cys2 sequences. 
HBs 2, 3, 5, 14, 54, 60, 64, and 131 were found in both sequence types. HB36, HB79, and 
HB88 could only be detected in cys4 sequences (Appendix 1 and 2). 
 
4.6.3 Distribution motif in expressed var DBL1α sequence 
Nine different DBL1α sequences amplified from cultured parasite cDNA of one severe 
malaria case were identified. Four sequences showed similarities of 97-99%, differing 
minimally in HB5 and 14 and might be considered as the same. var gene expression was 
also investigated by RNA extraction of dried blood on filter paper. The sequences were 
mostly similar to those derived from the genomic DNA of each isolate.  
Analysis using a cysteine/PoLV classification of cultured parasite cDNA (Pap1) showed 
sequence group 2 once, sequence group 3 five times and sequence group 4 three times 
(Table 4.4). Meanwhile, two var gene sequences from blood filter paper of severe cases 
belonged to sequence group 1 and two to sequence group 3. But, solely one case of 
uncomplicated malaria showed a DBL1α sequence tag by amplification belonging to 
sequence group 1. Amplification of two other uncomplicated cases yielded single bands 
but sequencing results showed less than 12% similarity with DBL1α. 
 
Tabel 4.4. Distribution motif of expressed var DBL1α sequences 
Cysteine/PoLV grouping (cys2) Cysteine/PoLV 
grouping (cys4) 
Cysteine/ 
PoLV 
grouping 
(cys 
others) 
RNA 
Source 
Group 1 
(sequence) 
Group 2 
(sequence) 
Group 3 
(sequence) 
Group 4 
(sequence) 
Group 5 
(sequence) 
Group 6 
(sequence) 
Filter 
paper 
3 0 2 0 0 0 
Culture 0 1 5 3 0 0 
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All expressed sequences extracted from filter paper of severe cases and two third 
extracted from culture of severe patient consisted of only two cysteine residues as shown 
in table 4.4, consistent with presence of HB 60 and absence of HB 36 (Appendix 2). Three 
sequences derived from cDNA of the cultured parasites presented 4 cysteine residues 
(cys4) and showed HB 36 in three sequences and HB60 in two sequences (Appendix 1). 
 
4.7 Identification of conserved DBL domains 
DBL domains were also identified from genomic DNA and cDNA by using degenerate 
UNIEBP primers (3.1.12). The primers were designed for the relatively conserved motifs 
of DBL domains. Amplification of genomic DNA resulted in multiple fragments ranging 
from nearly 250 bp to 1 kb in all samples as presented in figure 4.8. Samples originating 
from the same geographical area tended to present similar patterns of amplified bands 
i.e. Pap1, Pap2 and Pap3 which came from Papua and Kal1, Kal2, Kal3, Kal4 and Kal5 
which originated from South Kalimantan. Samples from South Kalimantan generated 
more amplified fragments then those of from Papua. Sequencing of the 525 bp band 
corresponded to a var gene coding for DBLγ isolated in Gabon, the 445 bp fragment 
matched with a var gene coding for PfEMP-1 from an isolate associated with placental 
malaria in Malawian women. 
 
 
 
 
 
 
 
 
Figure 4.8. Amplification of genomic DNA by using UNIEBP primers. Each sample 
yielded multiple bands ranging from nearly 250 bp to 1 kb. Samples from the same 
geographical area tended to present similar pattern of amplified fragments. 
 
Amplification of cDNA generated one to four bands ranging from 250 bp to 
approximately 600 bp in four out of five severe malaria patients, and no band observed 
from cDNA of uncomplicated cases although they had quantifiable RNA. Sequencing of 
a 418 bp fragment matched with the Plasmodium falciparum eba-175 gene and a 316 bp 
corresponded to DBL1α domain. A 486 bp band matched with the DBLγ domain isolated 
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from placenta of Malawian women with PAM and var1CSA of 3D7. This band was only 
found in a male patient from Papua (Pap3).  
 
4.8 Detection of var D-like gene 
To investigate the association of expressed specific motifs with severe malaria outcome, 
var D-like specific primers (3.1.12) were designed based on the 525 bp fragment of the 
PCR product that resulted from UNIEBP primers, as reported by Ariey and colleagues 
(2001). Amplification using var D-like specific primers resulted in multiple fragments 
from genomic DNA of all samples, but generated a single ∼237 bp fragment of expressed 
sequences from four severe malaria patients only. Sequence identity to the previously 
reported var D gene (AJ277137) (Ariey et al., 2001) was 29.0, 27.8, 27.0 and 19.3 % for var 
D-like sequence of Kal2, Pap3, Pap1 and Pap2, respectively. 
Our var D-like sequences showed 80-94% identity with the DBLγ fragment of PfEMP-1 
from several isolates including 3D7, Malawian isolates from patients with pregnancy-
associated malaria (PAM), placental isolates from Gabon, Kenya and Malawi (Figure 
4.9). However, further analysis showed three conserved motifs containing 6-10 
nucleotides within all four of our sequences (Figure 4.9). 
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Figure 4.9. Multiple aligment of specific var D-like sequences. Specific primers 
designed for the Indonesian var-D like sequence resulted in sequences corresponding to 
different sequence types including the DBLγ domain of PfEMP-1 isolated from 3D7 
[XM_001351285] and patients in association with PAM [AF547123]. Sequence identity of 
29.0, 27.8, 27.0 and 19.3 % was shown for var D-like sequence of Kal2, Pap3, Pap1 and 
Pap2 respectively to the previously reported var D gene (AJ277137). Black boxes: 
conserved motifs containing of 6-10 nucleotides. 
 
Analysis using varDom 1.0 server showed the conserved motif in HB3 and HB5, one 
sequence shared HB86 with the previously reported var D gene (Table 4.5). Of interest, 
HB86 was mainly found in DBLγ domain while the proposed var D gene (AJ277137) was 
reported to correspond with DBLδ domain. Another sequence showed HB27 and HB98, 
one other sequence presented HB82 and the rest showed only HB3. 
 
Table 4.5. Distribution of homology blocks (HBs) among the proposed var D gene 
using VarDom server 
 
Score S2b subdomain Sequence Score 
HB3 HB82 HB86 HB98 HB27 HB624 
HB5 
Pap1.var D-like - 26.5 - - - - 16.4 
Pap2.var D-like 24.6 - - - - - - 
Pap3.var D-like 31.3 - - 30.1 14.7 - 22.5 
Kal2.var D-like 35.5 - 32.0 - - 18.1 - 
AJ277137 (var D) 37.4 - 32.6 - - - 32.2 
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4.9 Identification of DBLβ-C2 domain of PfEMP-1 
Specific primer for the DBLβ-C2 sequence were designed according to several referred 
sequences of the DBLβ-C2 domain (2.1.12): JDP8 (AY028643), isolate IT4/24/25 (IT-
ICAM var) (AY578326), clone A4 strain IT4/25/5 (L42244.1), clone A4tres isolate IT 
(AF193424) and FCR3var CSA (AJ133811). After a series of PCR optimisation, 
amplification of genomic DNA generated 1-2 fragments in most samples, except for 
isolate Pap3 that presented additional bands of 500 bp and 600 bp, but all samples had a 
band of nearly 1.7 kb. Two samples had a similar pattern of amplified fragments (Figure 
4.10).  
 
 
 
 
 
 
 
 
 
 
Figure 4.10. Amplification results using specific DBLβ-C2 primer from genomic DNA 
of field isolates. All samples had a band nearly 1.7 kb with one or two additional bands 
around 3 kb  (Pap1, Kal1) or 600 bp and 500 bp (Pap3). Kal3 and Kal4 presented similar 
pattern of amplified band. A ∼1.7 kb fragment was used for cloning to identify the 
DBLβ-C2 sequences of field isolates. 
 
Considering the length of DBLβ-C2 domain from referred sequences, we took the ∼1.7 kb 
band and cloned them into a pGEMT-Easy vector. Four to seven clones for each sample 
were sequenced twice from both strands using SP6 and T7 primers. Due to the length of 
DBLβ-C2 sequences, we did primer walking by designing specific primers of the DBLβ-
C2 sequence of each sample in order to identify the inner part of the sequences (3.1.12). 
Derived from eight field samples, ten different sequences out of thirty-seven sequenced 
clones were identified (Figure 4.10). Each sample possessed one DBLβ-C2 sequence type, 
except for Pap2 and Pap3 had two sequence types. Three DBLβ-C2 sequences from three 
different samples (Kal1, Kal3, and Kal5) presented more than 99% sequence similarity, 
all three samples were originated from the same geographical area but had different 
clinical manifestations, Kal1 was from patient suffering from severe malaria but Kal3 
and Kal5 from uncomplicated malaria patients. Nucleotide blasting using NCBI database 
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demonstrated 76–84% identity with DBLβ domain of PfEMP-1 from distinct P. falciparum 
isolates except for Pap2 with 98% identity with PfEMP-1 of IT4/25/5 strain. The amino 
acid blasting also showed 96% identity with the PfEMP-1 of IT4/25/5 strain for Pap2 but 
a range of 44–53% identity with the PfEMP-1 proteins of several P. falciparum field 
isolates. 
Our DBLβ domains except Kal2.DBLβ shared many similar features including twelve 
cysteine residues and blocks of highly conserved amino acids which are flanked by more 
extensive polymorphic regions as previously described by Smithb and colleagues (2000).  
Similar to the Smith’s description concerning the consensus feature of DBLβ and C2 
domain, the DBLβ domain is followed by the C2 domain which varies in length, 
containing four invariant cysteine residues (Figure 4.11). Twelve conserved cysteine 
residues in DBLβ domain are numbered as C1-C12 and the C2 domain are C13–C16. 
Multiple sequence alignment with other DBL domains both from PfEMP-1 DBL and EBA 
DBL revealed that those 12 cysteine residues correspond to C1, C4, C5, C5a, C6, C6a, C7, 
C7a, C8, C8a, C9 and C10, as the conserved cysteine residues are identified with an 
Arabic numeral and a letter to indicate their position and to maintain the original 
nomenclature for identifying cysteine (Table 4.6).  
 
Tabel 4.6. Position of cysteine residues within DBLβ-C2 domain of field isolates 
corresponding to those of both PfEMP-1 DBL and EBA DBL. 
 
Sequence Cysteine residues numbering 
DBL domain 
consensus for 
PfEMP-1 and EBA 
C1 C4 C5 C5a C6 C6a C7 C7a C8 C8a C9 C10 
DBLβ domain of 
field isolates 
C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 
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Figure 4.11. Characteristic of DBLβ-C2 sequences from field isolates. DBLβ domain of 
Indonesian field isolates shared many similar features including twelve cysteine residues 
and blocks of highly conserved amino acids flanked by more extensive polymorphic 
regions. The DBLβ domain is always followed by C2 domain containing four invariant 
cysteine residues. The conserved cysteine residues in DBLβ-C2 are numbered as C1 - 
C16. The four loops (loop 1-4) and ‘Y motif’ are indicated by boxes. 
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Compared to another DBLβ-C2 sequences, Kal2.DBLβ-C2 sequence presented the most 
different sequence feature, it lacked several conserved cysteine residues, including C6, 
C8-C11 of DBLβ domain and C13, C15 and C16 of C2 domain. Despite many differences 
with the consensus feature of DBLβ and C2 domain, Kal2.DBLβ-C2 sequence exhibited 
the ‘Y motif’ within C2 domain which was reported to play an important role in binding 
function of DBLβ-C2 domain. Some DBLβ-C2 sequences also revealed little differences 
such as Kal3 had one more cysteine residue in between C5 and C6, Kal5 lacked of C11 
and was substituted by arginine (R) and Pap1 had serine (S) to substitute C12. However, 
all sequences (Kal3, Kal5 and Pap1) had the ‘Y motif’ within C2 domain (Figure 4.11). 
For further confirmation, analysis by using varDom 1.0 server 
(http://www.cbs.dtu.dk/services/VarDom/) was conducted. It was shown that all 
sequences except for Kal2 were identified as DBLβ domain. Although Kal2 was not 
identified as DBLβ domain, it remained to be classified as Duffy binding domain (Table 
4.7). HB analysis for DBLβ domain demonstrated the presence of five major HBs (HB1-5) 
in all sequences (Table 4.8), moreover HB53 in subdomain S1, HB146 in subdomain S2b, 
HB59 in subdomain S3a and HB61 and HB62 in subdomain S3b appeared as HB 
characteristics of DBLβ domain (Appendix 3). 
 
Table 4.7. Sequence family classification of DBLβ-C2 domain from field isolates using 
varDom server  
 
Score for sequence family classification DBLβ-C2 sequence 
Duffy-binding domain DBL β domain 
Pap1 345.0 719.0 
Kal1 393.1 858.0 
Pap2.1 384.2 855.4 
Pap2.2 384.1 855.6 
Kal2 255.3 - 
Pap3.1 357.6 703.1 
Pap3.2 368.6 823.7 
Kal3 383.7 844.6 
Kal4 377.3 784.7 
Kal5 380.3 832.6 
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Table 4.8. Distribution of five major homology blocks (HB) in DBLβ domains of field 
isolates using VarDom server 
 
DBLβ 
Sequence 
Score HB4 Score HB3 Score HB5 Score HB2 Score HB1 
Pap1 31.8 37.2 39.7 37.2 23.7 
Pap2.1 36.6 33.4 37.8 37.2 25.5 
Pap2.2 36.6 33.4 37.8 37.2 25.5 
Pap3.1 31.6 34.8 36.7 37.2 33.8 
Pap3.2 33.0 37.3 37.5 37.2 21.5 
Kal1 34.3 37.4 45.7 37.2 23.4 
Kal2 32.9 34.6 44.8 20.6 - 
Kal3 34.3 37.4 45.7 31.4 23.4 
Kal4 34.3 37.4 45.7 37.2 23.4 
Kal5 34.3 33.4 45.7 37.2 11.3 
 
 
4.9 Binding capacity of PfEMP-1 DBLβ-C2 domain to ICAM-1 
Specific primers for the binding site of DBLβ-C2 domain from each sample were 
designed to construct recombinant plasmids expressed on the surface of mammalian 
COS-7 cells and tested for binding to ICAM-1. Due to previous studies which have 
mapped the binding residues for ICAM-1 in both DBLβ and C2 domain, specific primers 
for each DBLβ-C2 sequence were designed including residues of C1-C16 (3.1.12). The 
domain was cloned in frame with the signal sequence and the transmembrane segment 
of HSV gD to allow expression on the surface of transfected COS-7 cells as previously 
described (Chitnis and Miller, 1994). Immunofluorescence assay using a monoclonal 
antibody, DL6 or ID3, which is directed against HSV gD sequences in the fusion 
constructs (Cohen et al., 1988) were applied to confirm that all constructs tested were 
expressed on the surface of transfected COS-7 cells. Magnetic beads coated with ICAM-
1/Fc were used for binding to transfected COS-7 cells expressing the DBLβ-C2(C1-C16) 
domain of each sample on their surface (Figure 4.12). 
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(a)       (b) 
 
 
 
 
 
 
 
Figure 4.12. Immunofluorescence images from the staining of transfected COS-7 cells 
with an antibody against an epitope tag in the recombinant protein. (a) ICAM-1 coated 
magnetic beads bound transfected COS-7 cells expressing recombinant DBLβ-C2 of field 
isolates. Binding was expressed when transfected cells contained five or more ICAM-1 
coated beads. (b) Transfected COS-7 cells expressing recombinant DBLβ-C2 of field 
isolates did not bind to ICAM-1 coated magnetic beads. 
 
Recombinant constructs derived from samples with the clinically severe malaria 
presented a higher ICAM-1 binding avidity (85.0–94.5%) compared to those from 
uncomplicated malaria, except in one sample, Pap3 with only 1% binding avidity (Table 
4.9). Interestingly, Kal3.DBLβ-C2 recombinant construct which has 99.8% and 99.4% 
sequence similarity with the Kal1.DBLβ-C2 and Kal5.DBLβ-C2, respectively, showed no 
binding avidity to ICAM-1 whereas the other two samples showed high binding avidity. 
Further, Kal3.DBLβ-C2 and Kal5.DBLβ-C2 which derived from samples with 
uncomplicated malaria demonstrated contrary binding avidity to ICAM-1. Surprisingly, 
Kal2.DBLβ-C2 showed high binding avidity despite the sequencing results showing low 
similarity with the other sequences and DBLβ-C2 in general. The mock-treated beads 
defined as magnetic beads without ICAM-1/Fc coating and untransfected COS-7 cells 
were used as negative controls for binding to ICAM-1. 
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Table 4.9. Binding capacity of DBLβ-C2 domain to ICAM-1 
Sample Clinical Binding to ICAM-1 (%)a 
Pap1.DBLβ-C2 Severe malaria 94.5 
Kal1.DBLβ-C2 Severe malaria 89.0 
Pap2.DBLβ-C2 Severe malaria 80.0 
Kal2.DBLβ-C2 Severe malaria 85.0 
Pap3.DBLβ-C2 Severe malaria 1.0 
Kal3.DBLβ-C2 Uncomplicated malaria 0 
Kal4.DBLβ-C2 Uncomplicated malaria 0 
Kal5.DBLβ-C2 Uncomplicated malaria 88.4 
Mock-treated beadsb - 0 
Untransfected cells - 0 
 
a  DBLβ-C2 recombinant proteins were expressed at the surface of COS-7 cells and tested 
for binding to ICAM-1/Fc coated beads. Data shown is a percentage of transfected COS-
7 cells containing five or more ICAM-1 coated beads in two independent experiments, 
with a minimum of 50 transfected cells were analyzed for each construct.  
b Binding was controlled with mock-treated beads i.e. beads without ICAM-1/Fc 
coating. 
 5. DISCUSSION 
 
 
5.1 Human Plasmodium knowlesi cases 
The detection of P. knowlesi in this study broadens the geographic distribution of natural 
P. knowlesi infection in humans. Although this is not surprising as there were previously 
many human P. knowlesi infections reported in the Malaysian part of Borneo. All four P. 
knowlesi infections were microscopically misdiagnosed as P. falciparum, as the early ring 
stage of P. knowlesi is morphologically similar with the early ring stage of P. falciparum. 
There was also a mixed infection with P. falciparum in three samples. 
By using Pmk8 and Pmkr9, the sequencing results confirmed solely one out of four 
positive samples by the PCR. A similar result was reported from Vietnam where only 
two out of five positive samples with P. knowlesi by PCR were positive confirmed by 
sequencing. The Pmk8 and Pmkr9 primers target the ssrRNA-S gene expressed during 
the sexual stage. The sequence of the reverse primer Pmkr9 is found in P. vivax S-type 
strains and other Plasmodium spp., especially related to P. vivax. The forward primer 
Pmk8 on the other hand seemed to be more specific. Imwong and colleagues found that 
these P. knowlesi primers (Pmk8 and Pmkr9) stochastically cross-react with P. vivax 
genomic DNA resulting in false positive amplification when there is P. vivax genomic 
DNA in the sample. All samples in this study were mixed infections with P. vivax, as 
molecularly confirmed by PCR. Based on the results, it is recommended to confirm by 
sequencing especially in cases of mixed infection. Furthermore, sequencing helps to 
detect genetic variation of different Plasmodia species and populations from distinct 
areas. 
The patient infected with P. knowlesi had clinically mild malaria and was successfully 
treated with chloroquine-primaquine. This is similar to the report by Putaporntip and 
colleagues that all P. knowlesi-infected patients in Thailand had a low parasite density 
and responded well to antimalarial drugs for either P. vivax (chloroquine-primaquine) or 
P. falciparum (mefloquine-artesunate). However, Cox-Singh and colleagues reported four 
fatal cases of P. knowlesi infection in Sarawak. All patients were relatively old (39-69 
years old), presented with hyperparasitaemia and developed marked hepatorenal 
dysfunctions defined as signs of severe P. falciparum malaria. It has been suggested that 
the high parasite load and the compounding effect of 24 hours asexual replication cycle 
lead to the fatal complication in P. knowlesi infection. A previous study demonstrated 
that P. knowlesi is able to loose or increase its virulence during blood passages in human. 
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Strain differences could also occur in wild populations and might effect human 
differently (Coatney, 1971), resulting in a range of clinical manifestation from 
uncomplicated to potentially life-threatening malaria. 
Regarding the large distribution of the vector and the natural host of P. knowlesi, it is 
very likely that P. knowlesi will be found in other parts of Indonesia. Since P. knowlesi is 
only reliably diagnosable by molecular methods, further molecular and clinical studies 
should be encouraged and new specific primer based on Indonesian P. knowlesi isolates 
designed.  
 
5.2 Characteristic of malaria patients 
Malaria presents with a broad range of clinical manifestations from asymptomatic to 
severe malaria leading to death. Once malaria takes a severe course, multiple organs are 
affected. Our severe malaria patients were adult and had cerebral malaria along with 
one or more of WHO-defined severe clinical manifestations including severe anaemia, 
respiratory distress, renal failure, hepatic dysfunction and jaundice. The patients features 
were similar to a large study in South-East Asia with predominantly adult patients and 
strictly defined severe malaria where 54% of the 1050 patients had cerebral malaria, 
37.1% renal impairment, 50.4% jaundice, 34.4% respiratory distress, 59.4% metabolic 
acidosis and 18.4% severe anaemia (Dondorp et al., 2008). There are distinct patterns of 
severe malaria according to malaria transmission intensity. In sub-Saharan Africa where 
the transmission intensity tends to be high and stable, severe malaria is mainly a disease 
for children under 5 years with cerebral malaria, severe anaemia or respiratory distress 
(Marsh et al., 1995). Also in areas with moderate transmission, cerebral malaria in young 
children is the most common presentation (Reybun et al., 2005; Snow et al., 1994). 
Conversely, in areas with low transmission, such as South-East Asia, severe malaria 
affects all age groups, but young adults are the most affected and commonly present 
with multiple organ failure including cerebral malaria, renal failure, severe jaundice and 
pulmonary oedema (White, 1987). Further, a study from a low transmission area in Asia 
showed that age has a large effect on presented syndromes, with anaemia, respiratory 
distress and convulsion being more common in children, whereas renal and hepatic 
failures are more often found in adults (Dondorp, et al., 2008).  
A number of age-specific rates of morbidity and mortality from epidemic falciparum 
malaria in Asia have been described, adults seem consistently to be at higher risk of 
severe disease (Dondorp et al., 2008; Mohanty et al., 2003; Greenberg and Lobel, 1990; 
Baird et al., 1998; Schwartz et al., 2001). Our severe patients were people from Java who 
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are at little or no risk of malaria infection but they moved to either Papua or South 
Kalimantan where malaria endemicity is higher. Those severe patients were considered 
to be first exposed to malaria infection. Bairda and colleague (1998) reported an increased 
risk of severe disease following primary exposure to P. falciparum with age among trans-
migrants moving from another part of Indonesia with lower risk of malaria infection to 
Irian Jaya (now Indonesian Papua) with the highest malaria endemicity in Indonesia. An 
intrinsic age-related difference in immune function is suggested leading to differences in 
the balance between protective and harmful effects of host immune responses to P. 
falciparum, profoundly affecting the course of infection.  
Contrasting with most of our severe patients, the uncomplicated malaria patients were 
residents of malaria endemic area. In an area with high transmission intensity, adults are 
less affected to infection due to naturally acquired immunity that was developed during 
the long-lived exposure to the parasites. Baird (1995) hypothesised that in malaria 
endemic areas, naturally acquired immunity has dual aspects; an intermediate phase 
referred as anti-disease or anti-toxic immunity which appears in young children exposed 
to heavy infection, where the infected individual showing minimal or no signs of clinical 
malaria even in the presence of high parasitaemia, and a true anti-parasite immunity 
occurs in adults which preclude high-density parasitaemia and attendant disease. All of 
our uncomplicated cases presented with mild malaria and low parasitaemia level, 
indicating an existence of anti-parasite immunity. 
 
5.3 Genotyping results 
It was shown that infections in humans are frequently composed of a complex mixture 
of parasite clones with different genetic and phenotypic characteristics (Ntoumi et al., 
1995; Conway and McBride, 1991; Greenwood et al., 1987). The number and relative ratio 
of the various clones present at any time point vary substantially from individual to 
individual. Analysis of the genetic characteristics of parasite populations using PCR und 
subsequent RFLP provide the advantage of sensitivity and certain specificity. The single 
copy genes MSP-1, MSP-2 and GLURP present large allelic polymorphisms, allowing 
easy detection of parasite diversity. However, the approach using PCR commonly 
underestimates the actual number of distinct alleles presents in the peripheral circulation 
at the time of sampling due to some reasons: (1) distinct parasite clones carrying the 
same allelic form are not differentiated, (2) alleles with identical size may present 
sequence differences that are not distinguished (Miller et al., 1993), (3) alleles present at 
very low density in a complex blood infection remain undetected (Kiwanuka, 2009). 
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Genotyping resulted in multiple infections per patient shown as multiplicity of infection 
(MOI). The MOI ranged from two to ten in each isolate, whereas samples from severe 
patients had higher MOI than those from uncomplicated cases. The result was consistent 
with a case series reported from India: mild cases had fewer clones compared to severe 
cases (Ranjit et al., 2004; Ranjit et al., 2005). However, other data on the association of 
MOI with disease severity showed conflicting results. Contrasting with our finding, 
studies in Senegal (Robert et al., 1996) and Nigeria (Amodu et al., 2008) reported lower 
MOI in severe malaria than in mild cases. But, reports from Madagascar (Durand et al., 
2008), Gabon (Mayengue et al., 2007) and Sudan (A-Elbasit et al., 2007) found no 
association between the MOI and severity of malaria. The variability of the results 
between studies may be in part due to differences in transmission levels according to 
study sites, differences in genotyping methods and/or interpretation of data and 
differences in sensitivity and accuracy used in different laboratories (Faernert et al., 2001; 
Felger et al., 1999; Smith et al., 1999). One potential explanation for our results could be 
that the higher the MOI the higher is the possibility of developing severe disease. The 
probability of being infected with a drug-resistant strain, a more pathogenic strain or an 
unknown strain to the host’s immune systeme is rising with rising MOI. Finally, it 
should be noted that malaria outcome is certainly not only determined by parasite 
characteristics, also host characteristics are involved. Several factors have been suggested 
influence the MOI including the age of the host (Ntoumi et al., 1995), human genetic 
polymorphisms (Ntoumi et al., 1997) and the levels of malaria endemicity and 
transmission intensity (Arnot, 1998). 
The study only focused on the association of MOI with levels of malaria endemicity and 
transmission intensity. As predicted, samples from Papua had a higher MOI than those 
from South Kalimantan. Papua province is a malaria stable transmission area and has 
high endemicity class with PfPR2-10 > 40% (Elyazar et al., 2011). It has high malaria 
transmission intensity where individuals receive more than one infection per year 
(Karyana et al., 2008). In contrast, South Kalimantan province is a malaria stable 
transmission area with moderate endemicity class, 5%< PfPR2-10 <40% (Elyazar et al., 
2011). Some studies reporting the relationship between the mean number of genotypes 
per infected person and transmission intensity suggested that increase in transmission 
level is generally associated with progressive increase in the average number of malaria 
parasite clones per host (Appawu et al., 2004). This indicates that in areas with lower 
transmission intensity infected persons should significantly have fewer parasite clones 
(Paul et al., 1998; Paul et al., 1995). Furthermore, the antigenic and genetic repertoire of 
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P. falciparum populations is wider in high-transmission areas (Bendixen et al., 2001; 
Hoffman et al., 2001; Faernert et al., 2009). Due to crossing and random mating between 
gametes belonging to different parasite clones, intragenic recombination and 
independent chromosome assortments during meiosis in the mosquito occur more 
frequently (Babiker et al., 1994). This has important consequences for the global spread 
of multigenic phenotypes such as vector competence, parasite virulence and anti-
malarial drug resistance (Paul et al., 1995). 
 
5.4 var gene diversity 
var gene diversity was determined by DBL1α region using αAF and αBR primers. 
Although the var gene sequences have an extensively diverse organisation, the majority 
of var genes contain the DBL1α region. The existence of homology blocks within this 
region has enabled researchers to design primers that can be used to amplify a DBL1α 
domain from the majority of samples (Taylora et al., 2000) including field isolates (Bull et 
al., 2007).  
In this study, the DBL1α region of P. falciparum field isolates derived from severe and 
uncomplicated malaria patients from two different malaria endemic areas in Indonesia 
was analysed. Consistent with previous studies on var gene diversity (Smith et al., 1995; 
Smithb et al., 2000; Taylora et al., 2000; Ward et al., 1999), our results demonstrated 
similar variability of DBL1α sequences within and between isolates. This implies that the 
level of diversity represents the overall DBL1α heterogeneity that exists within each 
isolate.  
Barry and colleagues reported the global diversity in P. falciparum var genes from 
different geographic regions. The diverse repertoire showed spatial structuring but 
minimal overlap in the var gene repertoire among isolates from different regions, 
indicating a global distribution of patterns (Barry et al., 2007). Our data demonstrated 
little overlap of field isolates from geographically close regions; only four sequences 
were shared each in two different isolates from the same geographical area. Comparison 
with published sequences also presented minimal overlap among DBL1α sequences 
from more different origins, concurred with previous studies that genetically diverse 
parasites contained essentially non-overlapping var gene repertoires (Freitas-Junior et al., 
2000), indicating that var gene diversity on a global scale is immense.  
Var sequence diversity is generated by frequent recombinations and rearrangements 
within or between var genes, specifically through either reciprocal recombination or gene 
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conversion (Taylorb et al; 2000; Freitas-Junior et al., 2000; Kyes et al., 2007). The 
frequency of recombination between var genes depends upon chromosomal location, 
gene orientation and homology in the gene flanking sequence (Ups). Var gene 
recombination preferentially occurs within rather than between var groups, with the 
exception of the semi-conserved var homologs (var1CSA, var2CSA and type 3 var) that 
appear to recombine on their own (Kraemer et al., 2007). Further, recombination 
processes can occur within each parasite genome as well as between two parasite 
genomes during both meiosis (Freitas-Junior et al, 2000; Taylorb et al; 2000) and mitosis 
(Duffy et al., 2009). This recombination hierarchy is globally maintaining the nature of 
the distinct var gene groups.  
However, selection is suggested to have a strong role in conserving var gene 
organisation, indicated by appearance of common sequences among global isolates. As 
var genes encode for variant target immunity and cytoadherence activity, the selective 
forces to maintain both functions have been manifested in an apparent genetic grouping 
of binding phenotypes to particular var gene sequences (Roberts et al., 1993). 
 
5.5 Distribution motif in DBL1α sequences from genomic DNA 
The DBL1α sequence tag was classified by using the cysteine/PoLV sequence grouping 
and the new homology block defined by Rask et al (2010). The distribution of sequence 
groups and HBs among isolates causing severe and uncomplicated malaria was similar, 
indicating that DBL1α shares common sequences among different clinical categories. 
According to the cysteine/PoLV sequence classification, the majority of sequences from 
both clinical categories belonged to sequence group 4 having four cysteine residues 
(cys4), referred as normal number of cysteine in DBL1α. Bull and colleagues (2007) 
demonstrated that the majority of group B var genes, which are the most frequent 
members of var genes, of group B/C and group C in laboratory isolates 3D7, HB3 and 
IT4 belonged to sequence group 4. Almost all group A var genes lacking two cysteine 
residues (cys2) are classified into sequence group 1-3, while sequence group 1 is 
exclusively found in group A var gene and approximately 60% of group A var gene 
belongs to sequence group 3, none of the cys2 type was found in group C var gene (Bull 
et al., 2005). Interestingly, we observed that group 3 sequences were only found in 
isolates having caused severe malaria. Although, we focused on DBL1α from genomic 
DNA, the result still provides information on the potential expression of var genes, 
where the parasite express a different var gene in every cycle through the switching 
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mechanism. Furthermore, studies on the association of expressed var gene with severe 
malaria reported a tendency of DBL1α with reduced cysteine residues to be expressed in 
severe malaria (Kirchgatter et al., 2002; Kyriacou et al., 2006). 
Since we used the field isolates originated from two distinct geographical areas, we 
further analyzed the distribution motif of DBL1α sequence tag in association with the 
geographical origin. Concurred with a previous study which reported a similar 
distribution of relative number of genomic sequences in each sequence group between 
field isolates and laboratory isolate 3D7 (Bull et al., 2005), our result revealed a similar 
sequence distribution between isolates, suggesting that although extremely diverse, 
DBL1α shares common feature among different geographical origins. 
By analyzing DBL1α sequence tags from three different continents, Bull et al. (2007) 
demonstrated an association of specific features i.e. MFK* at PoLV1 (group 1) or the 
*REY at PoLV2 (group 2 and 5) with short sequences. Our result showed similar 
associations, indicating that the same structural features in DBL1α sequences are shared. 
Homology block (HB) analysis by varDom server (Rask et al., 2010) showed that our 
DBL1α sequences stretch from the most prevalent HB3 to HB2. Unfortunately, we could 
not detect the HB17 and HB19 as HB characteristic for DBL1α due to the length of our 
sequence, since HB17 and HB19 lie upstream of HB4. The difference between cys4 and 
cys2 could only be detected by HB36 that was present in all cys4 but absent in all cys2 
sequences, as described previously (Rask et al., 2010). The presence of HB79 and HB88 in 
some cys4 sequences and absence in cys2 raising the possibility of those HBs for 
differentiating cys4 from cys2. 
 
5.6 Expressed var genes from clinical field isolates 
Besides using genomic DNA, var sequence diversity was also analysed using RNA 
transcripts extracted from dried blood on filter paper. This showed the expression of var 
genotypes at the time of symptoms. cDNA sequences from all severe cases but solely one 
of uncomplicated case could be generated. Interestingly, Maeno and colleagues (2008) 
using transcripts from dried blood on filter paper reported that the positivity rate of 
transcripts from asymptomatic patients was lower than from symptomatic cases. 
Regular PCR is a stochastic process and primer bias is a major source of error in semi-
quantitative expression trials. Even after repeated several times, amplification of cDNA 
from these two uncomplicated cases resulted in reproducible sequences with less than 
12% similarity with DBLα and only short sequences matched with hypothetical or 
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conserved proteins from Plasmodium. Although the universal primers αAF and αBR 
have shown to have only a small degree of bias in their specificity and possess a wide 
range in targeting var gene sequences, we could not excluded a primer bias as a cause of 
the undesired result. 
Previous studies showed contradictory data on the timing of var gene transcription, 
reverse transcription-polymerase chain reaction (RT-PCR) data suggested that many var 
gene types are transcribed in early ring stages and exclusively one major PfEMP-1-
encoding type is transcribed in later pigmented trophozoite stages (Chen et al., 1998; 
Scherf et al., 1998), whereas northern blot data showed that almost all full-length var 
transcripts encoding PfEMP-1 type were detected only in ring stages (Keys et al., 2003). 
Others argue that a single full-length var gene is transcribed both in ring and trophozoite 
stages in clonal parasites (Dahlback et al., 2007; Duffy et al., 2002; Noviyanti et al., 2001; 
Peters et al., 2002). However, most agree that only one var gene is dominantly expressed 
as a single PfEMP-1 in the late ring stage and mature trophozoite stage of parasite. The 
presence of a dominant transcript is proposed due to higher level of that transcript and 
rapid decay of low-level, spurious short- and sometimes full-length transcripts (Rowe et 
al., 1997; Mok et al., 2007; Chen et al., 1998).  
A study argued that RT-PCR of ring stages, as we did in this study, is the wrong method 
to find the major var gene transcript present in a given parasite sample. In most cases, 
mature forms of the parasite are not found in the peripheral circulation during infection 
due to adhesion of the IEs to microvascular endothelium and sequestration in variety of 
organs (Miller et al., 2002). This is the major question in studies of expression trials with 
field isolates if the parasites in the peripheral blood adequately represent the sequestered 
population. Ideally, studies addressing the relationship between var gene expression and 
specific disease syndromes have to examine sequestered parasites, but these are only 
accessible in post-mortem samples. Two studies indicated that the dominant parasite 
genotype of sequestered parasites is usually the same as in the peripheral blood (Dembo 
et al., 2006) and that the parasite genotype in cerebral malaria patients is homogeneously 
distributed throughout the body (Montgomery et al., 2006). In addition, by performing 
agglutination assays, Bull et al. (1998) observed a distinct parasite subset in peripheral 
blood of children with severe malaria compared to children with mild malaria, 
indicating the presence of virulent parasites in the periphery. Although these studies do 
not explain if the var gene profile of the peripheral blood parasites reflects that of 
sequestered population, they are consistent with the possibility that the peripheral blood 
population could adequately reflect the sequestered parasite. However, theoretically the 
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ring stages have a higher relative level of the relevant PfEMP-1-encoding var transcripts, 
but practically in several studies showed that pigmented trophozoites yield more RNA, 
so both stages should be valid for investigating repertoires of var transcription by RT-
PCR (Kyes et al., 2003). 
Observation of distribution motif in DBL1α showed a lack of two cysteine residues 
(cys2) in all DBL1α expressed sequences from patients. It is likely that sequences lacking 
two cysteine residues (cys2) are more frequently expressed than those with a normal 
number of cysteine (cys4). All DBL1α expressed sequences from blood of severe patients 
lacked of two cysteine residues. Unfortunately, sample size was too low to compare the 
DBL1α expression with those from uncomplicated patients. However, some studies 
comparing the expression between severe and uncomplicated case reported the 
tendency of cys2 DBL1α to be expressed in severe patients (Kirchgatter and del Potillo, 
2002; Bull et al., 2005; Kyriacou et al., 2006; Kraemer et al., 2007).  
Several studies about a possible association of either var gene grouping or DBL1α motifs 
with clinical malaria manifestations showed conflicting results. A study in Malian 
children with cerebral malaria showed predominantly expressed cys2 (referred as 
DBL1α1 type), characteristic of group A or B/A var gene, whereas a non-virulent form 
with hyperparasitaemia showed predominantly expressed cys4 (referred as DBL1α0 
type), characteristic of group B or C var gene (Kyriacou et al., 2006).  Another study 
using a selected 3D7 clone reported an association of up-regulation of group A var gene 
and expression, which can be detected on the surface of IE carrying PfEMP-1 type, with 
severe malaria (Jensen et al., 2004). Conversely, a study in Papua New Guinea showed 
up-regulation of group B var gene in clinical disease (severe and mild) compared to 
asymptomatic infection with predominantly expressed group C var gene (Kaestli et al., 
2006), but it should be noted that the severe disease in this study included a variety of 
clinical syndromes and not strictly defined cerebral malaria. A study from Tanzania also 
found an increased expression of both group A and B var genes in severe compared to 
uncomplicated and asymptomatic patients (Rottmann et al., 2006). Another study in 
Kenya did not find any association between expression of specific var gene groups and 
disease manifestations (Bull et al., 2005). In this study, we did not directly detect the 
upstream sequence (Ups) of expressed sequences to differentiate the var gene group, but 
blasting results revealed that all expressed sequences had identity of 82-99% with the 
UpsA var gene from distinct isolates, indicating group A var gene expression in all of our 
samples (4 severe and 1 uncomplicated case). 
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Investigation of DBL1α sequence from one synchronised P. falciparum culture showed 
that both cys2 and cys4 sequences were expressed during trophozoite stage. Although a 
study reported that trophozoite-parasitized erythrocytes could be the best source of 
RNA to determine the dominantly transcribed and translated var gene (Blomqvist et al., 
2010), var gene expression changes may occur early in in vitro adapted cultures (Peters et 
al., 2007; Southwell et al., 1989). Therefore, one can assume that results from the cultured 
parasites might not represent the expression pattern in the patient. 
 
5.7 Conserved DBL domains 
To determine the association of specific sequences and clinical outcome of malaria, first 
genomic DNA and cDNA was amplified with UNIEBP primers, and an internal specific 
primer based on the amplified fragment was designed. The degenerated UNIEBP 
primers were designed from conserved amino acid sequences PRRQKLC (Homology 
block ‘B’ by Smith) and PQFLRW (Homology Block ‘H’ by Smith) in the DBL domain to 
allow amplification of expressed DBL sequences. As predicted, multiple bands were 
generated indicating the diversity of the parasite lines in each sample, as confirmed by 
genotyping results. The number of observed bands probably underestimates the number 
of amplifiable sequences due to overlapping of same size-products and the possibility of 
preferential amplification of some sequences over others (Peterson et al., 1995).  
The amplified sequences from the transcripts varied in number and length and were 
identified as transcripts from the single copy gene eba-175 and from the var gene family. 
As described previously (Peterson et al. 1995), both genes contain an adhesive DBL 
domain. The eba-175 gene encodes for the erythrocytes binding antigen (EBA)-175 
protein associated with erythrocyte invasion and the multi-copy var gene family encodes 
for PfEMP-1 served as cytoadherence ligand and mediated cytoadhesion and 
sequestration. Both proteins play important roles during the blood stage infection 
(Howell et al., 2006; Michon et al., 2002). It is proposed that DBL domains of PfEMP-1 
evolved from EBAs, because erythrocyte invasion is an essential property for survival 
and transmission of all Plasmodium species and cytoadherence is a restricted property of 
a subset of Plasmodium species such as P. falciparum, and P. reichenowi (Smithb et al., 
2000). 
One of the amplified transcripts was a 486 bp band that matched well with sequences 
from DBLγ domain of var1CSA 3D7 and DBLγ domain of placenta from Malawian 
women with PAM. It can be assumed that both sequences correspond to each other as 
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placental isolates commonly express DBLγ containing subtypes of var genes with 
homology to either 3D7var5.2 (varCOMMON) or FCR3varCSA (Winter et al., 2003). Though, 
this 486 band was only found in a male patient from Papua (Pap3). The sequence is 
probably a var1CSA-type gene (also defined as varCOMMON). var1CSA is highly conserved 
between isolates, reported as constitutively transcribed in approximately 60% of malaria 
infected children in Gabon (Winter et al., 2003) and in non-pregnant donors (Friedb and 
Duffy, 2002), and can be detected by RT-PCR in many isolates independent from stage 
and binding phenotype. It is therefore not a strict characteristic of isolates from pregnant 
women or placental malaria (Winter et al., 2003; Kyes et al., 2003). In 3D7, var1CSA is 
present on chromosome 5 (var5.2), it has an UpsA and is constitutively transcribed in the 
opposite direction to most other var genes. It lacks a regulatory intron and an acidic 
terminal segment (exon 2) and ends in telomeric repeat sequences (Rask et al., 2010). 
var1CSA encodes a large, hypothetical PfEMP-1 of a structure similar to previous 
placenta-binding PfEMP-1 but it is not present at the IE-surface possibly due to an 
absence of a potential trans-membrane anchor sequence and the internal ATS domain. 
The function of var1CSA for the parasite remains unclear. However the fact that some 
isolates do not contain the var1CSA transcripts indicate that the gene is not essential for 
the parasite survival (Winter et al., 2003). 
 
5.8 Specific motif var D-like sequence 
In a report concerning the association of a specific genotype with severe malaria, Ariey 
and colleagues (2001) have designed a specific var D gene primer. It was based on a 520 
bp band that resulted from amplification using UNIEBP primers and was observed in 
most of the severe patients. By using similar methods, we designed a specific primer 
targeting the var D-like gene. The amplified sequence corresponded partly to the var D 
gene reported previously (Ariey et al., 2001) but closely matched with the DBLγ domain 
of PfEMP-1 isolated from 3D7 and patients with PAM from various origins. According to 
Ariey et al, the var D gene possessed characteristics of the DBLδ domain, while our 
sequences corresponded to DBLγ domain of PfEMP-1. Further analysis found three 
conserved sequence motifs containing 6-10 nucleotides within all proposed var D genes. 
Analysis of homology blocks by using varDom server showed HB86 in the previously 
described var D gene and in one of our sequences which is mostly found in the 
subdomain S2 of DBLγ, while another var D-like sequences showed HB27 which is 
largely found in DBLδ and HB98 which is observed in some of both DBLδ and DBLγ 
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domains. One other sequence showed HB82 which is found in small number of DBLδ 
and DBLγ domains, and one showed only HB3 which is found in all DBL domains. As 
only HB3 to HB5 was covered, the origin of our sequences remains uncertain, either 
DBLγ or DBLδ is possible. Rask and colleagues discussed the reminiscences of DBLγ and 
DBLδ domains, which might explain the results (Rask et al., 2010).   
Interestingly, Ariey and colleagues reported an absence of the gene from most laboratory 
strains (FCR3, Palo Alto, FCC1, Tak9/100, Tak9/96, ItG2G1), while we observed a single 
fragment of 240 bp from the laboratory strain K1, which has a 25,7% similarity with the 
var D gene reported by Ariey (AJ277137).  
In this study, the var D-like was found in genomic DNA but not in RNA transcripts of 
uncomplicated malaria isolates. A low identity of our var D-like gene with previously 
proposed var D gene made it difficult to refer those sequences as the var D gene. 
However, the increased prevalence and programmed expression of those sequences 
containing certain HBs solely in severe malaria implies its involvement in the 
pathogenesis of malaria. Though, sample size in this study was too small to indicate 
statistically valuable information. 
 
5.9 PfEMP-1 DBLβ-C2 domain and its ICAM-1 binding capacity 
In Plasmodium falciparum, DBL domains are present in both EBA used during erythrocyte 
invasion and PfEMP-1 mediated cytoadherence. PfEMP-1 DBL domains diverged 
significantly from the presumed ancestral EBA DBL domains and cluster into six distinct 
sequence classes: α, β, γ, δ, ε, and X (Smithb et al., 2000). Whereas the EBA DBL domains 
contain 12-13 invariant cysteine residues (Adams et al., 1992), the absolute number of 
cysteine residues differs more significantly between PfEMP-1 DBL domains. However, 
homology between EBA and PfEMP-1 DBL domains ends shortly after the 10th cysteine 
residue and all the first 10 cysteine residues in EBA DBL can be identified in PfEMP-1 
DBL domain (Smithb et al., 2000).  
In this study, we identified the DBLβ-C2 domain of P. falciparum field isolates derived 
from patients with severe and uncomplicated malaria. Similar to the previous reports 
(Smitha et al., 2000; Chattopadhyay et al., 2004), multiple alignment analysis showed that 
the DBLβ sequences share many similar features, including 12 conserved cysteine 
residues (C1-C12) and blocks of strong amino acid conservation which are flanked by 
more extensive polymorphic regions, where the sequences are followed by the C2 
domain which varies in length, including four invariant cysteine residues (C13-C16). The 
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C2 domain is also characterized by the presence of the ‘Y motif’ which is suggested to 
have an important role in binding function. The presence of conserved cysteines and 
homology blocks in DBLβ-C2 domain suggested conserved structural features like 
helices and loops, which in turn indicate a similar general architecture. 
Expression of the DBLβ-C2 domain containing 16 conserved cysteine residues from 
different P. falciparum field isolates on the surface of COS-7 cells and binding assays with 
the ICAM-1 coated magnetic beads helped to identify the DBLβ-C2 domain as the 
ICAM-1 binding site. Previous studies by using the A4tres isolate (Smitha et al, 2000) and 
the JDP8 isolate (Chattopadhyay et al., 2004) showed that the ICAM-1 binding region lies 
in the DBLβ-C2 domain with 16 conserved cysteine residues, indicating that both DBLβ 
and C2 are required for ICAM-1 binding. However, not all DBLβ-C2 tandems bind 
ICAM-1. Recombination of DBLβ and C2 domain of ICAM-1 binding and non-binding 
isolates did not bind ICAM-1. Both DBLβ and C2 regions of ICAM-1 binding isolates 
seem to contain contact residues required for ICAM-1 binding (Mayor et al., 2005). 
Further, chimera containing the DBLβ and C2 domain from two different ICAM-1 
binding isolates also did not bind ICAM-1, suggesting the functional interdependence 
between two binding domains from the same protein (Springer et al., 2004). Truncated 
analysis demonstrated that the critical ICAM-1 binding regions are located between a 
conserved tryptophan (W) and the first half of the C2 domain including the ‘Y motif’ 
(Figure 4.10). However, the optimal binding activity is dependent upon residues in the 
first part of DBLβ domain (Springer et al., 2004). 
Multiple alignment of both ICAM-1 binding and non-binding DBLβ-C2 domains 
revealed that there is no common sequences shared by ICAM-1 binding DBLβ-C2 
domains or absent in non-binding DBLβC2 domains. It is therefore unlikely that the 
ICAM-1 binding site lies in a linear sequence stretch within DBLβ-C2 domain 
(Chattopadhyay et al., 2004). In addition, a neighbour-joining analysis indicated the 
difficulties to strictly distinguish ICAM-1 binding from non-binding sequences by 
traditional phylogenetic criteria because ICAM-1 binding sequences did not group 
separately from non-binders (Howell et al., 2008). 
The DBLβ-C2 domain use a common interaction site for ICAM-1 binding that maps to 
the equivalent glycan binding region in the EBA-175 F2 DBL domain, which consists of 
three distinct binding pockets referred to as glycan 5, glycan 1 and glycan 3, located at 
flexible loops (Tolia et al., 2005). Homology modelling also suggested that the first part 
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of C2 domain including ‘Y motif’ is actually part of the DBL domain, explaining the role 
of ‘Y motif’ in ICAM-1 binding function (Tolia et al., 2005; Singh et al., 2006). 
A study using high resolution conformation model for binding DBLβ-C2 domains and 
ICAM-1 showed that there are four DBLβC2 loop regions contributing to the site of 
ICAM-1 binding (Figure 4.10): loop 1 (E21 – V30), loop 2 (G112 – E120), loop 3 (K137 – 
D125) and loop 4 (T283 – N293). Loop 1 is more important for the interaction between 
DBLβ-C2 domain and ICAM-1 and the sequences might modulate the binding affinity in 
different P. falciparum strains (Bertonati and Tramontano, 2007). Two studies observed 
several conserved motifs in those loops such as threonin (T) residue in loop 1, a 
conserved 3-amino acid motif in loop 3 (Oleinikov et al., 2009) and alanin (A) or leucine 
(L) in loop 4 (Bertonati and Tramontano, 2007) from ICAM-1 binding sequences. 
However, our results demonstrated no amino acid conservation in those loops from both 
ICAM-1 binding and non-binding sequences, supporting previous reports that both 
sequences share no common sequences (Chattopadhyay et al., 2004) Classical 
phylogenetic criteria were not able to differentiate both sequences indicating no 
possibilities to predict binding function from sequence criteria alone (Howell et al., 
2008). From a perspective of protein interaction, it is known that ligand interactions are 
not significantly altered by substituting a single residue that participates in binding, as 
long as the substitution fits into the structure without clashes and does not affect 
structural integrity such as substitution in flexible loops (Weber, 1992). Mutagenesis 
study by substituting a residue in a loop supported this theory and revealed that the loss 
of binding to ICAM-1 is not due to one single substitution but a combinations of 
substitutions (Howell et al., 2008; Oleinikov et al., 2009). 
Our results showed that two sequences derived from two different samples with similar 
clinical manifestations revealed converse ICAM-1 binding avidity although they were 
99.8% identical. DBL-based primers used in this study, to obtain the DBLβ-C2 domain, 
only amplify a portion of the entire DBL domain. When expressed as recombinant 
proteins they might not fold properly and incorrect folding might affect the protein 
function. Moreover, since every protein is unique, false negative binding activity could 
not be excluded without direct proof of correct folding. We also observed that two 
chimeras derived from patients with different clinical malaria manifestations had a 
similar binding avidity to ICAM-1. But overall, DBLβ-C2 domains from severe patients 
showed higher binding avidity to ICAM-1 than those from uncomplicated patients. This 
observation is similar to previous studies (Newbold et al., 1997; Turner at al., 1994, 
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Turner et al., 1998) which reported the association of ICAM-1 binding capacity with 
disease severity. In contrast, a study in Malawian children showed that binding capacity 
to ICAM-1 was lowest in children with cerebral malaria (Rogerson et al., 1999). Studies 
in Thai field isolates found no correlation between ICAM-1 binding and the severity of 
disease (Udomsangpetch et al., 1996; Ockenhouse et al., 1991). However, the low affinity 
of most malaria parasites for ICAM-1 indicates that ICAM-1 only mediates initial rolling 
of IEs on the endothelial lining (Craig et al., 1997; Yipp et al., 2000). The binding to 
ICAM-1 is also relatively weak and can not alone trigger massive sequestration. For 
stable binding, other receptors such as CD36 and synergisms are most likely required 
(McCormick et al., 1997). Thus, resolution of the association between ICAM-1 adhesion 
and severe disease requires further examination of the adhesive performance of patient 
isolates from different clinical manifestations with a bigger sample size. 
ICAM-1 is a member of the immunoglobulin superfamily and contains five Ig-like 
domains that are expressed on the surface of a wide range of cell types including 
endothelial cells. The interaction site between PfEMP-1 and ICAM-1 has been mapped to 
the three β strands, termed B, E and D (the BED side) of the N-terminal Ig-like domain 
(Berendt et al., 1992; Ockenhouse et al., 1992; Tse et al., 2004). This site is distinct, but 
shows some overlap with the binding site for lymphocyte function associated antigen 1 
(LFA-1) and a high level of overlap with the fibrinogen binding site (Chakravorty and 
Craig, 2005). Although different PfEMP-1 proteins appear to bind to a similar region of 
ICAM-1, there are discrete variations in the specific contact residues, as it was shown to 
affect ICAM-1 binding affinity under flow conditions. It indicates that the ICAM-1 
binding ability has originated from a common variant, and differences in binding are 
probably dictated by the high degree of DBLβ-C2 sequence variation in the PfEMP-1 
(Cooke et al., 1994; Gray et al., 2003; Tse et al., 2004). 
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 6. SUMMARY 
 
Malaria is a global health problem with hundreds of million people around the world 
suffering from disease and estimated 1-3 millions deaths each year. There are four 
Plasmodium species causing malaria in humans: Plasmodium falciparum, P. vivax, P. ovale 
and P. malariae.,Recently, it has been reported that Plasmodium knowlesi, a monkey 
Plasmodium species in South-East Asian countries, causes epidemiologically relevant 
infections in humans, proposing P knowlesi as the fifth humanpathogen malaria species. 
Microscopically, it is difficult to differentiate P. knowlesi from P. falciparum and/or P. 
malariae. 
P. falciparum causes the most severe clinical symptoms and is mainly responsible for 
complicated and lethal disease due to malaria.  Two characteristics of P. falciparum seem 
to be relevant: (1) the capability to invade erythrocytes of all stages, thus resulting in 
very high parasitaemia, (2) the ability of infected erythrocytes to adhere to the vascular 
endothelium and other host cells (called cytoadherence). The latter might result in 
obstruction of the microcirculation leading to poor perfusion of host tissues, hypoxia, 
dysfunction of affected organs, resulting further in multiple organ failure. To avoid 
clearance by the human immune system, P. falciparum continuously changes its antigenic 
surface proteins which are susceptible to antibody recognition and attack. This 
phenomenon is called antigenic variation. One of the proteins responsible for 
cytoadherence and antigenic variation is P. falciparum erythrocyte membrane protein-1 
(PfEMP-1). PfEMP-1 is a polymorphic protein that varies in domain composition and 
binding specificity. It is encoded by the var gene family consisting of ~60 variable genes 
per haploid genome. PfEMP-1 possesses an extra-cellular and intra-cellular part. The 
extra-cellular part is highly polymorphic and contains NTS followed by three distinct 
binding domains: DBL, CIDR and C2. 
In this study, the P. falciparum var genes from Indonesian field isolates were 
characterised and the binding capacity to ICAM-1, one of the most important host 
receptors, were examined. One of the important questions was if any differences could 
be observed between isolates from patients with severe and uncomplicated malaria, 
according to the WHO criteria.  
Twelve Indonesian malaria patients who were microscopically diagnosed as P. 
falciparum, were enrolled in this study. Due to the detection of P. knowlesi infections in 
several neighboring countries of Indonesia, all samples were examined for P. knowlesi by 
PCR. Amplification using recently published primers Pmk8 and Pmkr9 generated a 
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single band of 153 bp in four samples from the South Kalimantan province, the 
Indonesian part of Borneo. All P. knowlesi-positive samples were mixed infections with 
P. vivax and/or P. falciparum and microscopically diagnosed as mono-infection of P. 
falciparum. Direct sequencing confirmed solely one P. knowlesi infection out of four 
positive samples by PCR. At the same time, it was found that the used primers 
stochastically cross-react with P. vivax genomic DNA resulting in false positive 
amplification when P. vivax genomic DNA is present. Hence, sequencing was 
recommended for definite confirmation of P. knowlesi. Further studies on genetic 
variation should be encouraged in order to design new specific primers based on 
Indonesian P. knowlesi isolates. 
For further investigations, 8 Indonesian samples with P. falciparum mono-infection were 
included: 5 with severe and 3 with uncomplicated malaria. First, the diversity of P. 
falciparum var genes was examined by using universal primers. To amplify the majority 
of the var gene repertoire, primers were used binding to highly conserved regions in 
DBL1α that are present in most of the var gene family members. We identified seventy-
one different sequences out of 104 DBL1α sequenced clones, resulting in an average of 
8.9 different DBL1α sequences per isolate. The average DBL1α sequence similarity 
within isolates was as high as among isolates, implying the overall DBL1α heterogeneity 
that exists within each isolate. Little overlap of field isolates from geographically close 
regions and among DBL1α sequences from more different origins occurred, indicating 
that var gene diversity on a global scale is immense. Phylogenetic analysis demonstrated 
no clustering of sequences regarding strain or geographical origin.  
In order to identify an association of restricted motifs in DBL1α domain with malaria 
clinical outcome, the DBL1α sequence was analysed by distribution of semi-conserved 
features (cysteine/PoLV1-4 grouping) and classified into six sequence groups. Overall, 
there was no evidence for a difference between DBL1α sequence motifs between severe 
and uncomplicated malaria (p=0.48), indicating common sequences in DBL1α are shared 
among different clinical categories. Interestingly, all sequences of group 3 containing 
cys2 (meaning DBL1α lacked two cysteine residues) were obtained from severe cases. 
Distribution of motifs in DBL1α showed cys2 type in all expressed sequences in vivo and 
in two third of expressed sequences from culture, supporting previous reports that cys2 
sequences are more frequently expressed than those with a normal number of cysteines 
(cys4). Some studies comparing the expression between severe and uncomplicated cases 
reported the propensity of cys2 DBL1α to be expressed in severe malaria patients. All 
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DBL1α expressed sequences from blood of severely ill patients showed cys2 but sample 
size was to small for comparison of the DBL1α expression in uncomplicated and severe 
malaria.  
Ariey and colleagues proposed a specific genotype called var D gene to be associated 
with severe malaria. The proposed var D gene matched with the DBLδ domain. By using 
a similar method, we designed a specific primer, targeting the ‘var D-like’ gene. 
Amplification yielded multiple fragments from genomic DNA of all samples, but 
generated a single ∼237 bp fragment of expressed sequences from four severe malaria 
patients only. Sequences highly (80-94% identity) matched with the DBLγ domain of 
PfEMP-1 from several isolates, sequence identity to the proposed var D gene was 29.0, 
28, 27 and 19% for var D-like sequence of Kal2, Pap3, Pap1 and Pap2, respectively. 
Interestingly, analysis by using varDom server presented homology block (HB) 
characteristics of DBLγ and DBLδ. Prevalence and expression of those sequences solely 
in severe malaria implies potential involvement in the pathogenesis of malaria. 
However, sample size in this study was too small to indicate statistically valuable 
information. 
To further analyse the var gene and PfEMP-1, we explored the DBLβ domain. This 
domain, in tandem with C2 domain binds ICAM-1 in some P. falciparum isolates. In this 
study, the P. falciparum DBLβ-C2 sequence from Indonesian’s field isolates was 
amplified. Specific primers for the DBLβ-C2 sequence were designed according to 
several referred sequences of the DBLβ-C2 domain. The amplified ∼1.7 kb band was 
cloned and sequenced. One to two different sequences in each sample were identified, 
but three sequences from distinct samples of the same geographical origin presented 
more than 99% sequence similarity. Blasting results corresponded to the DBLβ domain 
of PfEMP-1 from various P. falciparum isolates. The DBLβ sequences shared many similar 
features, including 12 conserved cysteine residues (C1-C12) and blocks of amino acid 
conservations which are flanked by polymorphic regions. The DBLβ domain is followed 
by the C2 domain that varies in length, including four invariant cysteine residues (C13-
C16). The C2 domain is also characterized by the presence of the ‘Y motif’ which is 
suggested to have an important role in binding function.  
The DBLβ-C2 domain with 16 conserved cysteine residues from eight P. falciparum field 
isolates was expressed on the surface of COS-7 cells for binding assays with the ICAM-1 
coated magnetic beads. Recombinant constructs derived from samples with clinically 
severe malaria presented a higher ICAM-1 binding avidity compared to those from 
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uncomplicated malaria, supporting previous reports on the association of ICAM-1 with 
severe malaria. However, resolution of the association between ICAM-1 adhesion and 
severe disease requires further examination of the adhesive performance. Isolates from 
patients with different clinical manifestations and much larger sample size are needed. 
 
 
 
 
 7. ZUSAMMENFASSUNG 
 
 
 
Malaria ist ein globales Gesundheitsproblem mit mehreren hundert Millionen Menschen 
auf der ganzen Welt, die jedes Jahr unter der Krankheit leiden, ca 1-3 Millionen der 
Erkrankten versterben. Es gibt vier verschiedene Malariaerreger des Menschen: 
Plasmodium falciparum, P. vivax, P. ovale und P. malariae. Erst vor kurzem wurde bekannt, 
dass P. knowlesi, eine bei Makakken verbreitete Plasmodien Spezies, in Südostasien zu 
epidemiologisch relevanten Infektionen und Erkrankungen beim Menschen führt und 
daher mittlerweile auch als fünfter humanpathogener Malariaerreger bezeichnet wird. 
Mikroskopisch ist P. knowlesi nicht sicher von P. falciparum und/oder P. malariae zu 
unterscheiden. 
P. falciparum verursacht die bei weitem schwersten Krankheitsverläufe und ist ganz 
überwiegend für komplizierte Verläufe und Todesfälle verantwortlich. Hierfür scheinen 
vor allem zwei Eigenschaften von P. falciparum bedeutsam zu sein: (1) die Fähigkeit der 
Erreger alle Erythrozyten zu parasitieren und damit hohe Parasitämien verursachen zu 
können, (2)  die Bindung parasitierter Erythrozyten an Gefässendothelien und andere 
Wirtszellen (Zytoadhärenz). Letzteres kann zur Obstruktion der Mikrozirkulation und 
damit zu verminderter Organperfusion mit Hypoxie und Gewebsschädigung und 
schliesslich zum Multiorganversagen führen. Um der menschlichen Immunabwehr zu 
entgehen, ändert P. falciparum kontinuierlich seine Oberflächenantigene, die anfällig für 
Antikörper-Erkennung und -angriff sind. Dieses Phänomen wird antigenische Variation 
genannt. Eines der Proteine für Zytoadhärenz und antigenische Variation bei P. 
falciparum ist das Erythrozytenmembranprotein-1 (PfEMP-1). PfEMP-1 ist polymorph 
und variiert in Zusammensetzung und Bindungsspezifität. Es wird von der var-Gen-
Familie, bestehend aus ~60 variablen Genen pro haploidem Genom, kodiert. PfEMP-1 
besitzt einen extrazellulären und einen intrazellulären Teil. Letzterer ist sehr polymorph 
und enthält drei verschiedene Domänen: DBL, CIDR und C2. 
In der vorliegenden Arbeit sollten die var-Gene von P. falciparum Patientenisolaten aus 
Indonesien charakterisiert werden und deren Bindungskapazität an ICAM-1, einem der 
wichtigsten Wirtsliganden der Zytoadhärenz untersucht werden. Eine der primären 
Fragestellungen war, ob es hierbei Unterschiede zwischen Isolaten von Patienten gibt, 
bei denen entsprechend den WHO-Kriterien eine komplizierte oder eine 
unkomplizierter Malaria vorlag. 
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Insgesamt standen 12 verschiedene Isolate von indonesischen Patienten zur Verfügung, 
die mikroskopisch als P. falciparum diagnostiziert worden waren. Aufgrund des 
Nachweises von P. knowlesi in mehreren indonesischen Nachbarländern wurden alle 
Proben zunächst mittels PCR auf P. knowlesi untersucht. Die Amplifikation mittels 
bereits veröffentlichter Primer (Pmk8 und Pmkr9) generierte eine einzelne Bande von 
153 bp in vier Proben aus der Süd-Kalimantan Provinz, dem indonesischen Teil von 
Borneo. Alle P. knowlesi-positiven Proben waren Mischinfektionen mit P. vivax und/oder 
P. falciparum und mikroskopisch als Mono-Infektion mit P. falciparum diagnostiziert 
worden. Die direkte Sequenzierung bestätigt lediglich eine P. knowlesi Infektion von vier 
PCR-positiven Proben. Gleichzeitig wurde festgestellt, dass die verwendeten Primer mit 
genomischer  DNA von P. vivax stochastisch kreuzreagieren, was zu falsch positiven 
Ergebnissen führte. Zur sicheren Bestätigung einer P. knowlesi Infektion ist daher eine 
Sequenzierung empfehlenswert sowie weitergehende Untersuchungen zur genetischen 
Variation der Spezies und zum Design neuer spezifischer Primer für indonesische P. 
knowlesi Isolate. 
Für die weiteren Untersuchungen standen somit 8 indonesische Feldisolate mit P. 
falciparum-Monoinfektionen zur Verfügung; 5 mit komplizierter und 3 mit 
unkomplizierter Erkrankung. Zunächst wurde die Diversität von P. falciparum var-Genen 
mittels universeller Primer untersucht. Um die Mehrheit des var Gen-Repertoires zu 
amplifizieren, werden Primer verwendet, die an hoch konservierte Regionen der DBL1α-
Domäne binden, welche in den meisten var Genen gefunden wird. Es konnten hierbei 71 
verschiedene Sequenzen von 104 sequenzierten Klonen von DBL1α bei durchschnittlich 
8,9 unterschiedlichen DBL1α Sequenzen pro Isolat identifiziert werden. Die 
durchschnittliche DBL1α Sequenz-Ähnlichkeit innerhalb der Isolate war so hoch wie die 
der Isolate untereinander, was für eine allgemeine DBL1α Heterogenität spricht. Es 
zeigte sich keine Überschneidung bei Feldisolaten von geographisch benachbarten 
Regionen oder bei DBL1α Sequenzen von unterschiedlicher Herkunft. Dies deutet auf 
eine var Gen-Diversität auf globaler Ebene von immensem Ausmaß. Phylogenetische 
Analysen zeigten kein Clustering bezüglich einzelner Parasitenstämme oder der 
geographischen Herkunft. 
Um eine Assoziation bestimmter Motive der DBL1α-Domäne mit dem klinischen Bild 
der Malaria zu identifizieren, wurden die Sequenzen auf semi-konservierte 
Verteilungsmuster (cysteine/PoLV1-4 Gruppierung) untersucht und in sechs Sequenz-
Gruppen klassifiziert. Insgesamt gab es keine Anzeichen für einen Unterschied von 
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DBL1α Sequenz-Motiven bei schwerer bzw. unkomplizierter Malaria (p = 0,48), die 
Sequenz-Gruppen von DBL1α waren auf alle klinischen Kategorien verteilt. 
Interessanterweise wurden alle Sequenzen der Gruppe 3 mit zwei Cysteinen in 
schweren Fällen gefunden (Cys2, statt vier Cysteine, Cys4, es fehlen also zwei Cystein-
Reste). 
Die Verteilung der Motive in DBL1α zeigte den Cys2 Typ in allen exprimierten 
Sequenzen in vivo und in zwei Drittel der exprimierten Sequenzen aus der Kultur. Dies 
bestätigte frühere Berichte, dass Cys2-haltige Sequenzen häufiger als Cys4-haltige 
exprimiert werden. Einige Studien beobachteten eine erhöhte Expression von Cys2-
haltigen DBL1α  Sequenzen bei schwerer Malaria im Vergleich zu leichten Fällen. Alle 
hier untersuchten exprimierten DBL1α Sequenzen aus dem Blut schwer erkrankter 
Patienten zeigte zwei Cysteinreste, aber die Stichprobengröße war zu klein für einen 
Vergleich der Expression von DBL1α zwischen unkomplizierter und schwerer Malaria.  
Ariey und Kollegen hatten die Expression eines bestimmten Genotypes, das so genannte 
var D-Gen, in Verbindung mit schwerer Malaria gebracht. Das vorgeschlagene var D-
Gen stimmte mit der DBLδ Domain überein. Durch die Verwendung einer ähnlichen 
Methode haben wir spezielle Primer für ein 'var D-ähnliches"-Gen konstruiert. Die 
Amplifikation ergab mehrere Fragmente aus genomischer DNA von allen Proben, 
erzeugte jedoch nur ein einzelnes Fragment von ca 237 Basenpaaren aus RNA von vier 
Patienten mit schwerer Malaria. Die Sequenzen zeigte große Ähnlichkeit (80-94%) mit 
der DBLγ Domain von PfEMP-1 unterschiedlicher Isolate. Die Sequenz-Identität mit dem 
vorgeschlagenen var-D-Gen betrug jedoch nur 29, 28, 27 und 19% für die jeweiligen 
Isolate. Eine Analyse unter Verwendung des varDom Servers zeigte interessanterweise 
Homologie-Block (HB) Charakteristiken von DBLγ und DBLδ. Die Expression dieser 
Sequenzen nur bei schwerer Malaria impliziert eine potentielle Beteiligung an der 
Pathogenese der Malaria. Allerdings war die Stichprobengröße in dieser Studie zu klein 
für eine statistisch valide Aussage. 
Zur weiteren Analyse des var-Gens und PfEMP-1 wurde die DBLβ Domäne untersucht. 
Diese Domäne kann im Tandem mit der C2-Domäne ICAM-1 binden. In dieser Studie 
wurde die P. falciparum DBLβ-C2-Sequenz aus den indonesischen Feldisolaten 
amplifiziert. Spezifische Primer für die DBLβ-C2-Sequenz wurden für die DBLβ-C2-
Domäne konstruiert und die ~1,7 kb-schwere amplifizierte Bande kloniert und 
sequenziert. Ein bis zwei unterschiedliche Sequenzen wurden in jeder Probe 
identifiziert, drei Sequenzen aus unterschiedlichen Proben derselben geographischen 
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Herkunft zeigten mehr als 99% Übereinstimmung. Die Sequenzen korrespondierten mit 
der DBLβ Domäne von PfEMP-1 verschiedener P. falciparum-Isolate. Die DBLβ 
Sequenzen teilten viele Gemeinsamkeiten, einschließlich der 12 konservierten Cystein-
Reste (C1-C12) und der Aminosäuren-Blöcken, die von konservierten polymorphen 
Regionen flankiert werden. Die nachfolgende C2-Domäne variiert in der Länge und 
zeichnet sich durch vier Cysteinreste (C13-C16) und ein so genanntes "Y Motiv" aus, das 
eine wichtige Rolle bei der Bindungsfunktion zu haben scheint. 
Die DBLβ-C2-Domäne der acht verschiedenen P. falciparum Feldisolate wurde je mit 16 
konservierten Cystein-Resten auf der Oberfläche von COS-7-Zellen für Bindungstests 
mit ICAM-1 exprimiert. Die rekombinanten Konstrukte der Isolate mit klinisch schwerer 
Malaria präsentierten eine höhere ICAM-1-Bindungsavidität im Vergleich zu denen mit 
unkomplizierter Malaria, wie es aufgrund früherer Studien erwartet wurde. Eine 
mögliche Assoziation der ICAM-1-Bindung mit schwerer Malaria erfordert jedoch 
weitere Untersuchungen der Bindungskapazität an einem wesentlich größeren 
Patientenkollektiv  mit unterschiedlichen klinischen Manifestationen und idealerweise 
aus verschiedenen Malariaregionen. 
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APPENDIX 
 
 
Appendix 1. Distribution of homology blocks (HB) in cys4 sequences from DBL1α 
domain, classification by Rask et al. using VarDom server 
Sequences from severe malaria cases, gDNA (white letters).  
Sequences from severe malaria cases, cDNA culture (orange letters).  
Sequences from uncomplicated malaria cases, gDNA (black letters) 
 
 
Score S2b Score S2c Sequence Score 
HB3 
Score 
HB5 
Score 
HB2 HB64 HB54 HB14 HB79 HB131 HB60 HB36 HB88 
Pap1.A2 15 37.8  17.8  34.3    38.1  
Pap1.A6 15.2 37.1  13.7  30.5    11.3  
Pap1.C3 15.2 35.2  10.5  10.0    44.5  
Pap1.15 15.2 34.1  19.7 11.2 31.6   12.1 43.7  
Pap1.22 15.2 40.4   11.1 37.9    50.2  
Pap1.35 15.2 34.2   15.6 25.6  10.5 10.5 40.3  
Pap2.A1 15.0 39.3   10.8 28.8 12.4   42.7 11.6 
Pap2.A2 17.9 37.6  12.3  31.8 14.3 25.8  45.4  
Pap2.A3 15.2 34.9  15.0 12.8 32    50.7  
Pap2.A5  34.4    24.6    47.5  
Pap2.B1 17.9 39.3   10.8 28.8 12.4   42.7 11.6 
Pap3.A11 15.0 37.6  12.3  31.8 14.3 25.8  45.4  
Pap3.B3 15.0 32.2   13.2 18.7 13.6   53.6  
Pap3.B6 15.2 36.4  14.9  29.9  18.1  48.2  
Pap3.C4 15.2 34.2 11.8   26.4   10.5 40.3  
Kal1.A1 15.0 33.8 11.5   20.0 15.1  15.3 50.2  
Kal1.A3 15.0 37.2  16.7  32.0 14.5   59.3 11.6 
Kal1.B1 15.0 37.0  13.5  25.5    48.5 11.6 
Kal1.B4 15.0 36.8 11.5  10.7 17.2    27.7  
Kal1.B7 18.1 37.0  14.8 18.2 33.0    45.1  
Kal1.B6 17.9 38.7 13.4 14.6 11.5 22.8   10.3 50.7  
Kal1.B8 18.1 40.2 13.4 15.3  29.1 18.2   33.2  
Kal1.B9 15.0 33.8 11.5   20.0 15.1  15.3 50.2  
Kal1.C1 12.5 40.2  16.9 19.1 34.6    51.4  
Kal1.C2 15.0 33.8    20.0 15.1  15.3 50.2  
Kal1.C5 15.0 35.8  14.7 10.3 27.0    55.5  
Kal1.C6 15.0 37.2  16.7  32.0 14.5   59.3 11.6 
Kal1.C7 15.0 33.8    20.0 15.1  15.3 50.2  
Kal1.C3  36.1  13.7  24.5    38.4  
Kal1.C4 17.9 38.0 11.5 19.7 16.6 27.0    10.2  
Kal2.A1 15.2 38.2 13.4 13.4 19.4 32.3    43.5  
Kal2.A2 15.2 35.6    30.5   10.4 48.2  
Kal2.A3 15.0 36.2  16.8  27.1 13.3   50.8 11.6 
Kal2.A4 15.0 35.7   13.1 20.2    27.1  
Kal2.B1 15.0 36.2  16.6 10.0 25.7    56.2 11.6 
Kal2.C1 15.2 38.2  13.4 19.4 32.3    43.5  
Kal2.C2 15.2 35.6    30.5   10.4 48.2  
Kal2.C3 15.0 36.2  16.6 10.0 25.7    56.2 11.6 
Kal2.C10 15.2 30.5  14.0 12.2 30.3   16.0 51.3 11.6 
Kal3.A1 19.4 38.0 11.8  11.5 28.6    46.0  
Kal3.E7 17.9 44.2    15.8   10.3 15.7  
Kal4.A2 17.9 35.6    17.0    39.4  
Kal4.A3 18.1 39.1    34.6    32.0  
Kal4.A32 18.1 46.5  14.8 13.6 39.8   12.3 35.5  
Kal4.A42 15.2   14.6 13.0 34.7 16.8   30.4  
Kal4.A43 18.1 39.2  14.6 13.0 34.7 16.8   37.2  
Kal4.A52  35.2 11.8 13.7  32.3  10.1  46.4 11.6 
Kal4.B2 17.9 38.7  13.8  26.2 18.2   35.4 11.6 
Kal4.B5 17.9 31.9  13.5  25.5    55.0  
Kal4.B12 15.0 35.3  14.1  28.3 13.4   47.5 11.6 
Kal4.B22 17.9 33.2    17.0    39.4  
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Kal4.C1 18.1 38.4  11.8  34.4  12.9  37.0 11.6 
Kal4.C22 15.0 32.4  14.1  28.3 13.4   47.5 11.6 
Kal4.C42 17.9 37.6  12.4  29.5 16.0   32.1  
Kal5.A4 15.0 35.3  14.1  28.3 13.4   47.5 11.6 
Kal5.B2 15.0 35.1    29.3   21.2 45.3  
Kal5.C3 15.2 37.0 13.4 14.8 18.2 33.0    45.1  
Kal5.C4 15.0 35.3  10.2 17.9 32.3    20.1  
Kal5.C5 12.5 37.1  15.3  28.4   11.5 43.1  
Kal5.C6 15.0 35.3  10.2 17.9 32.3    20.1  
Kal5.C7 15.0 35.3  10.2 17.9 26.3    20.1  
 
 
 
Appendix 2. Distribution of homology blocks (HB) in cys2 sequences from DBLα 
domain (classification by Rask et al. using VarDom server) 
Sequences from severe malaria cases, gDNA (white letters).  
Sequences from severe malaria cases, cDNA culture (orange letters).  
Sequences from severe malaria cases, cDNA filter paper (yellow letters on red). 
Sequence from an uncomplicated case, cDNA filter paper (yellow letters on black). 
Sequences from uncomplicated malaria cases, gDNA (black letters) 
 
 
Score S2b Score S2c Sequence Score 
HB3 
Score 
HB5 
Score 
HB2 HB64 HB54 HB14 HB79 HB131 HB60 HB36 HB88 
Pap1.A3 15.2 29.9    27.8   38.1   
Pap1.A4 15.2 36.7 11.8   30.7   48.2   
Pap1.B3 15.0 33.0    27.4   41.5   
Pap1.10 15.0 37.8    13.0   35.3   
Pap1.11 15.2 35.9   12.7 26.6   33.9   
Pap1.12 15.2 35.9   12.7 11.5   33.9   
Pap1.14 15.2 35.9   12.7 26.6   33.9   
Pap1.31 15.2 40.0  14.8 20.5 37.5   33.6   
Pap1.32 15.2 36.3 11.8  12.7 26.6   33.9   
Pap1.FP  35.9   11.6 26.6   33.9   
Pap2.C1 19.2 36.8  17.5 17.6 29.6   21.6   
Pap2.C2 18.1 36.4   11.2 26.1  18.2 47.7   
Pap2.C3 19.4 36.4 13.4  11.2 26.1  18.2 47.7   
Pap2.C4 19.4 33.1   11.1    35.4   
Pap2.FP 15.0 36.3 13.4   25.5   35.9   
Pap3.A1 15.0 38.2    21.8   44.8   
Pap3.A2 15.0 40.3    24.4   19.4   
Pap3.A8 15.0 29.5   13.3    34.2   
Pap3.A9 15.0 29.5 13.4  13.3    34.2   
Pap3.A10 15.0 29.5   13.3    34.2   
Pap3.C8 15.0 40.1  11.1  28.0   42.7   
Pap3.C9 15.0 40.1  11.1  28.0   42.7   
Pap3.FP  40.1 18.8 11.1  28.0   42.7   
Kal1.A2 15.0 34.8   11.5    39.2   
Kal1.B3 18.1 38.4  15.4 19.5 30.2   37.1   
Kal1.FP  37.4    19.1      
Kal2.B2 15.0 35.1 13.4   29.2   44.4   
Kal2.FP  37.4 14.5   27.3   43.5   
Kal3.F7 17.9 37.0    22.7   39.1   
Kal3.F10 17.9 38.6    24.6   40.8   
Kal4.C62 17.9 34.5    15.5   35.2   
Kal5.C1 15.0 34.5 13.4   15.5   43.7   
Kal5.C2 15.0 37.4    27.3   43.7   
Kal5.C8 15.0 37.4    27.3   43.7   
Kal5.FP 15.0 36.3 13.4   25.5   35.9   
 
 Appendix 3. Distribution of homology blocks (HBs) in subdomain of DBLβ domain of field isolates using varDom server. 
 
Scor
e S1 
Score S2a Score S2b Score S2c Score S3a Score S3b Seque
nce 
HB 
53 
HB 
13 
HB 
266 
HB 
189 
HB 
146 
HB 
14 
HB 
199 
HB 
131 
HB 
174 
HB 
436 
HB 
187 
HB 
589 
HB 
183 
HB 
59 
HB 
250 
HB 
382 
HB 
119 
HB 
62 
HB 
209 
HB 
61 
HB 
30 
HB 
129 
HB 
18 
Pap1 30.2 34.9    11.9     17.4   33.0    19.5  49.5   23.6 
Pap2.1 30.2 39.9   12.4 24.1       26.4 40.9  11.2    57.0   25.0 
Pap2.2 22.7 39.9    24.1       26.4 40.9  11.2    57.0   27.4 
Pap3.1 32.0 33.7   10.9 10.9      16.1  28.5    25.4  51.1  11.6 31.6 
Pap3.2 27.9 20.7  15.3 12.7 14.9  11.3  11.6    24.8 11.5  14.0 36.7  61.0   29.9 
Kal1 12.0 29.9 12.7  11.9 31.3 13.4       30.7 14.7  19.4 33.8 33.9 57.1   33.5 
Kal2 27.9 20.9  13.7  21.8   10.0  18.6       21.4  17.6 14.0  25.8 
Kal3 27.8 29.9 12.7  11.9 31.3 13.4       30.7 14.7  19.4 33.8 33.9 57.1   33.5 
Kal4 27.9 29.9 12.7  11.9 31.3 13.4       30.7 14.7  19.4  21.3 57.1   33.5 
Kal5  29.9 12.7  11.9 31.3 13.4       30.7 14.7  19.4 33.8 33.9 57.1   33.5 
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Appendix 4. Ethical clearance for the study from Medical Faculty, Brawijaya 
University, Indonesia. 
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Appendix 5. Pictures during field research in Indonesia.  
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